

Mucolytic bacteria license pathobionts to acquire host-derived nutrients during dietary nutrient restriction

Kohei Sugihara¹, Sho Kitamoto¹, Prakaimuk Saraithong², Hiroko Nagao-Kitamoto¹, Matthew Hoostal², Alexandra Rosevelt¹, Chithra K Muraleedharan³, Merritt G. Gilliland^{3rd 1}, Jin Imai¹, Maiko Omi⁴, Shrinivas Bishu¹, John Y. Kao¹, Christopher J. Alteri⁵, Nicolas Barnich⁶, Thomas M. Schmidt², Asma Nusrat³, Naohiro Inohara³, Jonathan L. Golob², and Nobuhiko Kamada^{1,7,8}

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

² Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

³ Department of Pathology, University of Michigan, Ann Arbor, MI, USA

⁴ Department of Biologic and Materials Sciences and Prosthodontics, University of Michigan School of Dentistry, Ann Arbor, MI, USA

⁵ Department of Natural Sciences, University of Michigan, Dearborn, MI, USA

⁶ M2iSH, UMR1071 Inserm/University Clermont Auvergne, Clermont-Ferrand, France

⁷ WPI Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan

⁸ Lead Contact

Address correspondence to:

Nobuhiko Kamada, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, 1150 West Medical Center Drive, Ann Arbor, MI 48109.

E-mail: nkamada@umich.edu

Disclosures:

The authors declare no competing interests.

1 **SUMMARY**

2 Pathobionts employ unique metabolic adaptation mechanisms to maximize their growth in disease
3 conditions. Adherent–invasive *Escherichia coli* (AIEC), a pathobiont enriched in the gut mucosa of
4 patients with inflammatory bowel disease (IBD), utilizes diet-derived L-serine to adapt to the inflamed gut.
5 Therefore, the restriction of dietary L-serine starves AIEC and limits its fitness advantage. Here, we find
6 that AIEC can overcome this nutrient limitation by switching the nutrient source from the diet to the host
7 cells in the presence of mucolytic bacteria. During diet-derived L-serine restriction, the mucolytic symbiont
8 *Akkermansia muciniphila* promotes the encroachment of AIEC to the epithelial niche by degrading the
9 mucus layer. In the epithelial niche, AIEC acquires L-serine from the colonic epithelium and thus
10 proliferates. Our work suggests that the indirect metabolic network between pathobionts and commensal
11 symbionts enables pathobionts to overcome nutritional restriction and thrive in the gut.

12

13 **Keywords**

14 inflammatory bowel disease; L-serine; adherent-invasive *Escherichia coli*; *Akkermansia muciniphila*;
15 intestinal mucus barrier

16

1 INTRODUCTION

2 Microbial metabolism plays a critical role in cooperation and competition within the microbial community
3 (Passalacqua et al., 2016). Microbial metabolism rapidly responds to environmental stimulation, such as
4 host immune activation, dietary modification, and gut inflammation, to adapt to the surrounding
5 microenvironment (Becattini et al., 2021; Desai et al., 2016; Kitamoto et al., 2020; Sonnenburg et al.,
6 2005). For example, commensal symbionts reprogram the transcription of their metabolic genes in
7 response to host immune activation and alter their metabolic functions within several hours (Becattini et
8 al., 2021). Likewise, gut inflammation alters the luminal microenvironment, including nutrient availability
9 and oxygen levels, which, in turn, contributes to the alteration of the gut microbial composition and
10 function (Rigottier-Gois, 2013; Stecher, 2015). Metatranscriptome studies have shown that gut
11 inflammation upregulates stress response pathways and downregulates polysaccharide utilization and
12 fermentation in a murine model of colitis (Ilott et al., 2016; Schwab et al., 2014). In addition, chronic
13 intestinal inflammation upregulates stress response genes, including small heat shock proteins, which
14 protect commensal *Escherichia coli* from oxidative stress (Patwa et al., 2011). These disease-specific
15 microbial transcriptional signatures have also been observed in patients with inflammatory bowel disease
16 (IBD) (Schirmer et al., 2018). However, the impact of the transcriptional adaptation of microbes on host-
17 microbe interaction and disease course is largely unknown.

18

19 The gut microbiota plays a fundamental role in the pathogenesis of IBD (Ananthkrishnan, 2015;
20 Sugihara and Kamada, 2021). Potentially pathogenic members of the commensal bacteria, termed
21 pathobionts, have been identified in IBD patients and observed to trigger or exacerbate inflammation in
22 the gut. Adherent-invasive *Escherichia coli* (AIEC) is the most studied pathobiont associated with IBD.
23 The prevalence of AIEC increases in the ileal and colonic mucosae of IBD patients compared to non-IBD
24 control subjects (Nadalian et al., 2021). AIEC strains harbor several virulence genes related to the ability
25 to adhere and invade the intestinal epithelial cells (IECs) and thus are associated with the exacerbation
26 of intestinal inflammation and fibrosis (Carvalho et al., 2009; Imai et al., 2019). In IBD, AIEC may exploit
27 unique strategies to gain a growth advantage over competing, nonpathogenic, symbiont *E. coli* strains.
28 We have reported that AIEC reprograms metabolic gene transcription in the inflamed gut to adapt to the
29 inflammatory microenvironment (Kitamoto et al., 2020). In particular, AIEC upregulates L-serine
30 metabolism pathways that are crucial in acquiring a growth advantage over symbiont *E. coli* strains.
31 Interestingly, as luminal L-serine is supplied by diet, the modulation of dietary L-serine can regulate
32 intraspecific competition between AIEC and commensal *E. coli* (Kitamoto et al., 2020). Thus, dietary
33 modification can be an effective strategy to treat pathobiont-driven diseases, such as IBD.

34

35 L-serine is a nonessential amino acid that supports several metabolic processes crucial for the
36 growth and survival of mammalian and bacterial cells, especially under disease conditions (Newman and

1 Maddocks, 2017). For example, L-serine metabolism is markedly upregulated in cancer cells and immune
2 cells and plays a central role in their survival and growth (Ma et al., 2017; Maddocks et al., 2013;
3 Rodriguez et al., 2019). Moreover, consistent with gut bacteria, L-serine used in the proliferation of cancer
4 cells and immune cells is also supplied by the diet, and therefore a lack of dietary L-serine can inhibit the
5 proliferation of these cells (Ma et al., 2017; Maddocks et al., 2017).

6

7 Here, we report the impact of dietary L-serine on the host–microbe interaction during gut
8 inflammation. As the deprivation of diet-derived L-serine limits the fitness advantage of AIEC over
9 commensal *E. coli*, we anticipated that dietary L-serine restriction would improve gut inflammation in mice
10 colonized with conventional microbiota (specific pathogen–free [SPF] mice). However, to our surprise,
11 diet-derived L-serine restriction exacerbated dextran sodium sulfate (DSS)–induced colitis in SPF mice.
12 In our quest to explain this unexpected phenotype, we discovered that *Akkermansia muciniphila*, a
13 commensal symbiont capable of degrading mucin, is expanded in colitic mice under dietary L-serine
14 restriction. The expansion of *A. muciniphila* results in a massive erosion of the colonic mucus layer,
15 thereby allowing AIEC to relocate close to the host epithelial cells. In the epithelial niche, AIEC can
16 acquire L-serine from the host epithelial cells, whereby it can overcome dietary L-serine restriction and
17 proliferate. Thus, the mucolytic bacteria, such as *A. muciniphila*, can serve as an indirect metabolic
18 supporter for AIEC by licensing the acquisition of host-derived nutrients.

19

1 RESULTS

2 **L-serine metabolism is disturbed in the gut microbiota of IBD patients**

3 Our previous study showed that IBD-associated AIEC uses amino acid metabolism, particularly L-serine
4 catabolism, to adapt to the inflamed gut. Consistent with this notion, the IBD-associated AIEC strain LF82
5 rapidly consumed L-serine, more than other amino acids in the cultured media (**Figure S1**), indicating
6 that AIEC prefers L-serine as a nutrient source. However, it remains unclear whether L-serine plays a
7 central metabolic role in the more complex microbiota of IBD patients. To assess the microbial L-serine
8 metabolism, we first analyzed data available in the Inflammatory Bowel Disease Multi'omics Database
9 (IBDMDB) of the Integrative Human Microbiome Project (iHMP), which integrates metagenomic,
10 metatranscriptomic, metaproteomic, and metabolic data on the microbiome of IBD (**Figure 1A**). As
11 previous studies have reported (Lloyd-Price et al., 2019; Morgan XC, 2012; Vich Vila A, 2018), the
12 abundance of Enterobacteriaceae, including *E. coli*, is significantly higher in patients with ulcerative colitis
13 (UC) and Crohn's disease (CD), the two most common forms of IBD, than in non-IBD controls (**Figure**
14 **1B**). L-serine is biosynthesized from intermediates of the glycolysis pathway or from L-glycine, and it
15 converts to pyruvate, which is a necessary substrate for gluconeogenesis and the tricarboxylic acid cycle
16 (**Figure 1C**, right). Metagenomic analysis showed that the abundance of phosphoglycerate
17 dehydrogenase (PHGDH), the rate-limiting enzyme for serine biosynthesis from the glycolysis pathway,
18 was significantly reduced in both UC and CD patients compared to non-IBD controls (**Figure 1C**, left).
19 Conversely, the abundance of serine dehydratase (SDH), the enzyme that catalyzes the conversion of
20 L-serine to pyruvate, was significantly higher in the gut microbiota of UC and CD patients compared to
21 non-IBD controls (**Figure 1C**, left). Although metatranscriptomic profiles were more varied between
22 individuals than metagenomic profiles, these genes were also transcriptionally changed in IBD patients
23 (**Figure 1D**). These results suggested that bacteria that utilize L-serine, such as AIEC, are enriched in
24 the microbiota of IBD patients. In addition to microbial metabolism, we also confirmed the amino acid
25 levels in the feces of patients with IBD using the iHMP metabolome data (**Figure 1E**). Compared with
26 non-IBD controls, essential amino acids, particularly valine and histidine, were significantly higher in
27 patients with IBD. Importantly, nonessential amino acids, including serine, glutamate, and arginine, were
28 significantly lower in IBD patients than in non-IBD controls. Thus, it is likely that the gut microbiota of IBD
29 patients consumes more L-serine than the gut microbiota of non-IBD controls.

30

31 **The deprivation of dietary L-serine exacerbates DSS-induced colitis**

32 Given that the gut microbiota of IBD patients appeared to be enriched with L-serine utilizers, including
33 AIEC, we hypothesized that limiting L-serine availability may suppress the growth of potential pathobionts,
34 thereby reducing the susceptibility to colitis. As luminal L-serine levels are mainly regulated by diet-
35 derived L-serine (Kitamoto et al., 2020), we next examined the impact of dietary L-serine deprivation on
36 intestinal inflammation. To this end, specific pathogen-free (SPF) mice were fed either a defined amino

1 acid control diet (Ctrl) or an L-serine deficient (Δ Ser) diet, as previously defined (Kitamoto et al., 2020;
2 Maddocks et al., 2013). L-glycine was removed from the Δ Ser diet as L-serine and L-glycine may be
3 interconverted (Pizer LI, 1964). Mice were treated with 1.5% DSS for 5 days to induce colitis, followed by
4 conventional water for 2 days (**Figure 2A**). Unexpectedly, the Δ Ser diet-fed mice lost significantly more
5 body weight and had a higher disease activity index (DAI) than the Ctrl diet-fed mice (**Figures 2B** and
6 **2C**). Likewise, mice fed the Δ Ser diet had a greater degree of inflammation in the colon than the mice
7 fed the Ctrl diet (**Figures 2D–2F**). Notably, the Δ Ser diet did not affect body weight, colon length, and
8 histology in the DSS-untreated mice (**Figures 2B–2F**). To uncover the mechanism by which the restriction
9 of dietary L-serine exacerbates colitis, we focused on the role of the gut microbiota. As shown in **Figures**
10 **2G–2J**, the Δ Ser diet did not worsen colitis in germ-free (GF) mice. We confirmed the same phenotype
11 in SPF mice by depleting the gut microbiota with a cocktail of broad-spectrum antibiotics (**Figure S2**).
12 These results suggest that the gut microbiota is required for the exacerbation of colitis caused by the
13 restriction of dietary L-serine.

15 **Dietary L-serine starvation leads to the blooms of pathotype *E. coli* in the inflamed gut**

16 We next analyzed the gut microbiota isolated from Ctrl diet- and Δ Ser diet-fed mice to identify the
17 bacterial taxa that may be associated with the severe inflammation observed in Δ Ser diet-fed mice. We
18 found that the restriction of dietary L-serine affected the microbial composition during inflammation, while
19 in the steady state it had little influence (**Figure 3A**). Linear discriminant analysis effect size (LEfSe)
20 further identified the bacterial families over- and under-represented after the dietary change. LEfSe
21 analysis showed that Verrucomicrobiaceae and Enterobacteriaceae families were over-represented in
22 Δ Ser diet-fed mice, whereas Sutterellaceae and Porphyromonadaceae families were under-represented
23 (**Figure 3B**). Interestingly, the abundance of *E. coli*, which belongs to the Enterobacteriaceae family, was
24 significantly higher in the colitic mice fed the Δ Ser diet rather than the Ctrl diet (**Figure 3C**). To determine
25 the function of *E. coli* accumulated in Δ Ser diet-fed mice, the abundance of genes associated with
26 pathotypes of *E. coli* were evaluated by qPCR. Notably, genes associated with adhesion and invasion to
27 host epithelial cells (*vat*, *fimH*, *flicC*, *ompA*, *ompC*, and *ibeA*) and metabolic adaptation (*pduC*, *chuA*,
28 *fyuA*) were significantly enriched in Δ Ser diet-fed mice than in Ctrl diet-fed mice (**Figure 3D**). This result
29 suggests that *E. coli* strains accumulated in Δ Ser diet-fed mice may be pathotype *E. coli*, such as AIEC.
30 Similarly, the abundance of *Akkermansia muciniphila*, a major bacterial species in the
31 Verrucomicrobiaceae family, was significantly increased in the L-serine deficient condition (**Figure 3C**).
32 These data indicate that the restriction of dietary L-serine leads to the unexpected blooms of *E. coli*
33 harboring AIEC pathotypes, together with other commensal symbionts, such as *A. muciniphila*, in the
34 inflamed gut.

36 ***A. muciniphila* enables AIEC to relocate to the epithelial niche by degrading the mucus layer**

1 As AIEC requires L-serine for its fitness in the inflamed gut (Kitamoto et al., 2020), we did not expect
2 dietary L-serine restriction to induce an AIEC bloom. The suppression of AIEC growth by dietary L-serine
3 restriction in the setting of intraspecific competition (Kitamoto et al., 2020) suggests that other bacterial
4 species in SPF mice may act as metabolic supporters for AIEC to overcome the nutrient limitation. In this
5 regard, we focused on *A. muciniphila* as a metabolic supporter for AIEC. We first assessed the growth
6 kinetics of *A. muciniphila* and *E. coli* during colitis. As colitis progressed, the abundance of *A. muciniphila*
7 gradually decreased in Ctrl diet-fed mice (**Figure 4A**). In contrast, when dietary L-serine was restricted,
8 *A. muciniphila* was markedly increased on day 1 after DSS treatment and it maintained a higher
9 abundance until day 7 compared (**Figure 4A**). As *A. muciniphila* does not require L-serine for its growth
10 (Derrien et al., 2004), it may have a growth advantage over other commensal gut bacteria under the
11 nutrient-restricted condition. Of note, the abundance of *E. coli* (likely enriched with AIEC) was unchanged
12 in the early stage of colitis but dramatically increased at 7 days after DSS treatment with L-serine
13 starvation (**Figure 4A**). These results suggest that under these conditions, the expansion of *A.*
14 *muciniphila* may trigger the subsequent proliferation of AIEC.

15
16 *A. muciniphila* is a mucolytic bacterium capable of degrading mucus by several glycoside
17 hydrolases that target the host mucus glycans (Derrien et al., 2004). Thus, the expansion of *A.*
18 *muciniphila* may cause mucus barrier dysfunction. Consistent with this notion, we observed that the
19 thickness of the inner mucus layer was significantly reduced in the Δ Ser diet-fed mice after DSS
20 treatment, with the expansion of *A. muciniphila* (**Figures 4B and 4C**). Notably, in the steady state (i.e.,
21 without expanding *A. muciniphila*), the Δ Ser diet had no apparent effect on the mucus barrier (**Figures**
22 **4B and 4C**). As intestinal mucus acts as a physical barrier that keeps luminal antigens, including resident
23 microbiota, distant from the host epithelial cells (Johansson et al., 2008; Van der Sluis et al., 2006), a
24 defective intestinal mucus barrier may result in the penetration of luminal antigens and increase the risk
25 of colitis (Johansson et al., 2014; Van der Sluis et al., 2006). Consistent with this notion, dietary L-serine
26 deprivation increased intestinal permeability after DSS treatment (**Figure 4D**). Also, degradation of the
27 mucus layer by dietary L-serine restriction brought the luminal bacteria closer to the IECs (**Figure 4E**).
28 Thus, the *A. muciniphila* expansion may promote the encroachment of luminal bacteria, including AIEC,
29 close to the colonic epithelium, and it may contribute to the increased susceptibility to colitis. To validate
30 whether disruption of the mucus barrier under L-serine restriction facilitates the localization of AIEC to
31 the epithelial niche, SPF mice were fed the Ctrl diet or the Δ Ser diet to induce the *A. muciniphila*
32 expansion and subsequent mucus barrier disruption in colitic mice (**Figure 4F**). After disrupting the mucus
33 layer by the feeding of the Δ Ser diet, followed by DSS treatment, mice were challenged exogenously with
34 AIEC strains (LF82 and CUMT8) or commensal *E. coli* strains (HS and MG1655) (**Figure 4F**). As shown
35 in **Figure 4G**, the number of colonic mucosa-associated AIEC strains, but not commensal *E. coli* strains,
36 was significantly higher in the Δ Ser diet-fed mice (disrupted mucus layer) than in the Ctrl diet-fed mice

1 (intact mucus layer).

2

3 To further examine the direct interaction between *A. muciniphila* and AIEC in the gut, we
4 cocultured *A. muciniphila* and AIEC in the presence of a human-derived colonoid monolayer (HCM). As
5 *A. muciniphila* is an obligate anaerobe (Derrien et al., 2004), we used a two-chamber system that enables
6 the coculture of anaerobic bacteria in the upper anaerobic chamber and the HCM supplemented with
7 oxygen in the lower aerobic chamber (**Figure 5A**) (Lauder et al., 2020). In this culture system, the HCM
8 secreted mucin and formed a thick mucus layer on its surface (**Figure 5B**). After coculture with *A.*
9 *muciniphila*, the mucus layer was dramatically reduced (**Figure 5B**). In contrast, exposure to AIEC strain
10 LF82 did not affect the mucus layer on the HCM (**Figure 5B**). Notably, the presence of *A. muciniphila*
11 facilitated the encroachment of AIEC LF82 to the HCM (**Figure 5B**). This consequence was further
12 validated by enumeration of mucosa-associated AIEC. Consistent with the observations of
13 immunofluorescence staining, the association of AIEC LF82 with the HCM was significantly increased in
14 the presence of *A. muciniphila* (**Figure 5C**). Conversely, the number of nonadherent AIEC LF82 (i.e.,
15 floating in media) was even reduced when cocultured with *A. muciniphila* (**Figure 5C**). These findings
16 suggest that *A. muciniphila*-mediated mucus degradation facilitates the encroachment of AIEC to the
17 epithelial niche.

18

19 **AIEC and *A. muciniphila* cooperate to promote gut inflammation under dietary L-serine restriction**

20 Thus far, we determined that *A. muciniphila*, which can proliferate independent of L-serine, expands when
21 dietary L-serine is restricted and facilitates the epithelial localization of AIEC strains in the gut by
22 degrading the mucus layer. However, the link between AIEC–*A. muciniphila* interaction and the increased
23 susceptibility to colitis remained unclear. Hence, we next examined the involvement of this bacterial
24 cooperation in the exacerbation of colitis under dietary L-serine restricted conditions. To this end, we
25 generated gnotobiotic mice colonized by AIEC and *A. muciniphila*. To assess the importance of the
26 mucus-degrading capacity of *A. muciniphila*, we used a consortium of nonmucolytic bacterial strains as
27 the base bacterial community. We modified a known synthetic human gut microbiota (SM) model (Desai
28 et al., 2016). The original SM consortium is composed of 14 fully sequenced human commensal gut
29 bacteria representing the five dominant phyla, which collectively possess essential core metabolic
30 capabilities (Desai et al., 2016). We removed 4 species of mucolytic bacteria (*Bacteroides caccae*, *B.*
31 *thetaiotaomicron*, *Barnesiella intestinihominis*, and *A. muciniphila*) and commensal *E. coli* from the
32 original consortium. We defined this new base consortium composed of 9 species of nonmucolytic
33 commensal symbionts as the “nonmucolytic synthetic human gut microbiota” (NmSM) (**Figure 6A**). To
34 evaluate the interaction between AIEC and *A. muciniphila*, we added AIEC LF82 with or without *A.*
35 *muciniphila* to the base NmSM community (NmSM+LH82 and NmSM+LF82+Am) (**Figure 6A**). Likewise,
36 for the control groups, the commensal *E. coli* strain HS replaced AIEC LF82 (NmSM+HS and NmSM+

1 HS+Am) (**Figure 6A**). All mice were fed with the Δ Ser diet, and colitis was induced by DSS treatment
2 (**Figure 6A**). In the absence of *A. muciniphila*, and under dietary L-serine restriction, the colonization of
3 AIEC LF82 did not exacerbate colitis compared to the colonization of HS(**Figures 6B–6F**). The presence
4 of *A. muciniphila* did not alter the susceptibility to colitis in the commensal *E. coli* HS–colonized mice,
5 although colitis led to a marked expansion of *A. muciniphila* (**Figures 6B–6F**). These results indicated
6 that *A. muciniphila* can gain a growth advantage over other commensal symbionts in the gut when dietary
7 L-serine intake is limited; however, *A. muciniphila* per se is not colitogenic. Notably, unlike commensal *E.*
8 *coli*, cocolonization of AIEC LF82 and *A. muciniphila* significantly exacerbated colitis (**Figures 6B–6F**).
9 These results suggest that the colonization of AIEC alone is not sufficient to exacerbate colitis, whereas
10 *A. muciniphila* may promote the colitogenic capability of AIEC. Consistent with the severity of colitis, the
11 presence of *A. muciniphila* promoted the expansion of AIEC LF82, but not commensal *E. coli* HS, in both
12 fecal and mucosal compartments (**Figures 6G–6I**). These results demonstrated a causal role of the
13 interaction between AIEC and *A. muciniphila* in the exacerbation of colitis. It is noteworthy that this
14 pathogenic interaction is only observed in the absence of dietary L-serine. In the gnotobiotic mice fed the
15 Ctrl diet (i.e., L-serine–sufficient), the cocolonization of AIEC LF82 and *A. muciniphila* did not increase
16 the susceptibility to colitis (**Figure S3**). The maintenance of the intact mucus layer may explain this
17 phenotype (**Figures S3B and S3C**).

18

19 **AIEC exploits host-derived L-serine to counteract dietary L-serine deprivation**

20 We demonstrated that mucolytic bacteria promote the relocation of AIEC to the epithelial niche, where it
21 can evade nutrient (i.e., L-serine) restriction, proliferate, and facilitate intestinal inflammation. However,
22 the mechanism by which AIEC proliferates in the epithelial niche under dietary L-serine restriction
23 remained unclear. We hypothesized that AIEC exploits host-derived nutrients in the epithelial niche, as
24 some pathogens can liberate host-derived nutrients for their growth (Eisenreich et al., 2010). To
25 determine if AIEC uses host-derived nutrients for its growth, we first compared the growth of LF82
26 cultured with or without IECs. As shown in **Figure 7A**, the coculture of AIEC LF82 and IECs significantly
27 enhanced the growth of AIEC LF82 compared with the host cell–free condition. This bacterial growth
28 enhancement by IECs was not observed in the commensal *E. coli* strain HS, nor in the LF82 Δ fimH
29 mutant strain that lacks genes involved in adhesion to IECs (**Figure 7B**), which suggests that bacterial
30 adhesion to IECs is required for the utilization of host-derived nutrients. To identify the host-derived
31 nutrients used by AIEC in the epithelial niche, we analyzed the transcriptomic changes of AIEC LF82
32 induced by the association with the HCM (**Figure S4A**). RNA-seq analysis demonstrated that epithelial
33 association significantly altered the transcriptional profiles of AIEC LF82 (**Figure S4B**). The Gene
34 Ontology (GO) enrichment analysis showed that the coculture of AIEC LF82 and HCM upregulated the
35 pathways involved in AIEC growth, including ribosome biosynthesis and protein folding, response to
36 stress, and sugar transport (**Figure S4C**). In contrast, the pathways related to chemotaxis and amino

1 acid biosynthesis were downregulated (**Figure S4C**). In contrast, the presence of AIEC had a minor
2 impact on the transcriptomic profiles of the HCM (**Figures S4D** and **S4E**). Notably, AIEC LF82
3 upregulated genes related to L-serine metabolism and downregulated genes related to L-serine
4 biosynthesis when associated with the HCM (**Figure 7C**), indicating that AIEC acquires L-serine from the
5 host epithelium and uses it for its growth. In fact, IEC presence did not promote the growth of the
6 $\Delta tdc\Delta sda$ (ΔTS) mutant AIEC LF82 strain, which lacks two major L-serine utilization gene operons and
7 is incapable of utilizing L-serine (Kitamoto et al., 2020), unlike its effect on LF82 WT (**Figure 7D**).
8 Consistent with this finding, the association with AIEC LF82 significantly reduced the concentration of
9 free intracellular L-serine in the IECs, whereas the association with LF82 ΔTS had no effect (**Figure 7E**),
10 indicating that AIEC LF82 consumes L-serine in the infected host cells. Further, we confirmed that
11 although host-derived L-serine is not required for the initial AIEC adhesion and invasion, it is vital for AIEC
12 growth after it associates with the host cells. For example, early phase (1 h) adherence and invasion of
13 AIEC did not differ between the WT and the ΔTS mutant AIEC LF82 strains (**Figures 7F** and **7G**).
14 However, in the later phase (3 h), proliferation of AIEC after adherence and invasion was significantly
15 impaired in the ΔTS mutant strain compared to the WT strain (**Figures 7F** and **7G**). Interestingly, the
16 deprivation of L-serine from the media facilitated the adhesion and invasion of AIEC LF82 to IECs (**Figure**
17 **7H**). This evidence suggests that AIEC enhances its growth after adhering to host cells by utilizing host-
18 derived L-serine.

19

20 Lastly, we assessed the extent to which the utilization of host-derived L-serine by AIEC is linked
21 to the susceptibility to colitis. To this end, NmSM-colonized gnotobiotic mice were colonized with either
22 AIEC LF82 WT or ΔTS mutant AIEC LF82 together with *A. muciniphila* (**Figure 7I**). Both groups of mice
23 were fed the ΔSer diet, followed by a DSS challenge. The colonization of LF82 WT or the ΔTS mutant
24 was comparable in feces, whereas the number of AIEC associated with the colonic mucosa was
25 significantly lower in the ΔTS mutant strain than in the LF82 WT strain (**Figure 7J**), suggesting that AIEC
26 LF82 may exploit host-derived L-serine in the epithelial niche. Furthermore, consistent with the impaired
27 proliferation of AIEC in the epithelial niche, the mice colonized with the LF82 ΔTS mutant strain displayed
28 an attenuated degree of colitis compared to the mice colonized with the LF82 WT strain (**Figures 7K–**
29 **7O**).

30

1 DISCUSSION

2 In this study, we show that the biosynthesis and utilization of L-serine are disturbed in the gut microbiota
3 of patients with IBD, which is consistent with our recent research showing that the IBD-associated
4 pathobiont AIEC upregulates L-serine catabolism in the inflamed gut (Kitamoto et al., 2020). We had
5 expected that the deprivation of dietary L-serine would attenuate inflammation by suppressing the
6 expansion of pathobionts, such as AIEC. However, we observed that dietary L-serine restriction leads to
7 the expansion of AIEC and subsequent exacerbation of colitis. This unexpected and adverse effect of
8 dietary L-serine deprivation is context dependent. Dietary L-serine restriction promotes the abnormal
9 expansion of AIEC only when it coexists with mucolytic bacteria, such as *A. muciniphila*. The fact that L-
10 serine is a crucial nutrient for the growth of various gut bacteria, including AIEC, but not *A. muciniphila*,
11 gives *A. muciniphila* a growth advantage over other commensal microbes under L-serine restriction.
12 Notably, the blooms of *A. muciniphila* per se are not detrimental. However, amassed *A. muciniphila*
13 facilitates the encroachment of AIEC to the epithelial niche by degrading the mucus barrier. As a result,
14 AIEC can reside in the epithelial niche and counteract dietary L-serine restriction by extracting host-
15 derived nutrients. Notably, AIEC can acquire L-serine pooled in the host colonic epithelium. This novel
16 insight advances the understanding of the complex interplay among pathobionts, symbionts, and host
17 cells in the context of gastrointestinal diseases, such as IBD.

18

19 Dietary amino acids are vital nutrients for maintaining intestinal homeostasis and the gut
20 microbiota (Sugihara et al., 2018). L-serine is thought to be a conditionally essential amino acid as it
21 plays a critical role in the cellular metabolisms of both mammalian and bacterial cells only under certain
22 conditions (Kitamoto et al., 2020; Ma et al., 2017; Maddocks et al., 2017; Rodriguez et al., 2019). Several
23 biosynthetic and signaling pathways require L-serine, including the synthesis of other amino acids, the
24 production of phospholipids, and the provision of one-carbon units to the folate cycle, which are used for
25 the de novo synthesis of nucleotides (Yang and Vousden, 2016). L-serine also contributes to the
26 production of glutathione, which is essential for reducing toxic oxidants and metabolic byproducts. Thus,
27 L-serine supports several metabolic processes that are crucial for growth and adaptation to the
28 microenvironment. It has been reported that some *E. coli* strains rapidly consume L-serine, as compared
29 to other amino acids (Prüss et al., 1994). Notably, *E. coli* promotes the consumption of L-serine under
30 heat stress (Matthews and Neidhardt, 1989). Consistently, our work has demonstrated that bacteria
31 belonging to the Enterobacteriaceae family, including *E. coli*, use L-serine to adapt to the inflamed gut
32 (Kitamoto et al., 2020). Thus, some bacteria, most likely pathogens, utilize L-serine metabolism to
33 counteract environmental stress. The multi'omics database shows that L-serine metabolism is disturbed
34 in parallel with a lower fecal L-serine concentration in IBD. Although we need to clarify the mechanism
35 by which gut bacteria consume L-serine in IBD, certain bacteria may use L-serine to adapt to the
36 inflammatory microenvironment. How the concentration of luminal L-serine is regulated remains unclear.

1 Diet is the primary source of luminal L-serine, as dietary deprivation significantly reduces its concentration
2 in the gut lumen (Kitamoto et al., 2020). Regarding the consumption of L-serine, both host cells and
3 bacteria are L-serine utilizers in the gut (Caballero-Flores et al., 2020; Ma et al., 2017; Nagao-Kitamoto
4 et al., 2016). Generally, L-serine is contained in protein-rich foods, such as meat, fish, eggs, and
5 soybeans. A recent systematic review has shown that fiber and calcium intakes are insufficient in IBD,
6 whereas protein intake meets or exceeds the recommended amount (Lambert et al., 2021). Therefore,
7 the reduced concentration of L-serine in the gut lumen of individuals with IBD may be caused by the
8 excessive consumption of L-serine by the gut microbiota or the host cells rather than by the insufficient
9 intake of protein. As mentioned, L-serine plays a pivotal role in the fitness of certain bacteria, including
10 pathobionts such as AIEC, particularly when exposed to environmental stress. Consequently, pathobionts
11 may evolve backup systems to evade the shortage of such a vital nutrient. This seems to be a strategy
12 that pathobionts use to maintain a fitness advantage over commensal competitors in disease conditions.
13 In the present study, we found that AIEC can switch the source of L-serine from the diet to the host cells
14 when dietary L-serine is limited. To acquire host-derived L-serine, AIEC relocates its colonizing niche
15 from the gut lumen to the mucosa. Given the evidence that the availability of L-serine in the gut lumen is
16 decreased in patients with IBD, the enrichment of mucosa-associated AIEC in IBD may be triggered by
17 the perturbed amino acid homeostasis in the gut lumen.

18

19 As L-serine metabolism plays a vital role in the survival of some gut microbes, particularly
20 pathobionts, this metabolic pathway can be a therapeutic target for pathobiont-driven inflammatory
21 diseases, such as IBD. Our previous work showed that the dietary deprivation of L-serine suppresses
22 AIEC expansion (Kitamoto et al., 2020). In the current study, dietary L-serine deprivation resulted in the
23 unexpected expansion of AIEC. Thus, the therapeutic effects of the dietary intervention are context
24 dependent. In other words, the same dietary therapy could be either beneficial or detrimental. The factor
25 that dictates the efficacy of dietary interventions may be the basal microbiota composition of individuals.
26 For example, dietary L-serine restriction may not significantly impact patients who are not colonized by
27 AIEC or colonized by AIEC without coexistent mucolytic bacteria. In individuals colonized by AIEC and
28 metabolic competitors for AIEC (e.g., certain commensal *E. coli* strains) but lacking mucolytic bacteria,
29 dietary L-serine restriction can facilitate the competitive elimination of AIEC by the commensal *E. coli*
30 strains. Indeed, gnotobiotic mice colonized by the microbiota from a patient with CD displayed a reduction
31 of Enterobacteriaceae and the attenuation of colitis when L-serine was removed from the diet (Kitamoto
32 et al., 2020). This result implies that this individual had a sufficient number of metabolic competitors for
33 AIEC and the restriction of dietary L-serine prompted the competitive elimination of AIEC. On the other
34 hand, as shown in the current study, in the presence of mucolytic bacteria, AIEC can overcome nutritional
35 restriction and exacerbate colitis. Notably, *A. muciniphila* has a protective role in some individuals with
36 metabolic diseases, such as obesity and diabetes mellitus (Dao et al., 2016; Everard et al., 2013), and

1 therefore, it has been proposed as a probiotic bacterium (Cani and de Vos, 2017). Consistently, in the
2 present study, *A. muciniphila* colonization per se did not exacerbate colitis, even under dietary L-serine
3 restriction (with a noticeable *A. muciniphila* expansion). However, *A. muciniphila* can serve as a metabolic
4 supporter for AIEC, and hence, indirectly contribute to the pathogenesis of colitis. Thus, the balance of
5 pathobionts and their metabolic competitors and supporters may determine the outcomes of dietary
6 interventions.

7
8 Nutritional competition is one of the main strategies used by commensal symbionts to prevent
9 the colonization and proliferation of commensal pathobionts and exogenous pathogens (Cameron and
10 Sperandio, 2015; Guo et al., 2020). To overcome this symbiont-mediated colonization resistance,
11 pathogens have evolved various strategies (Perez-Lopez et al., 2016). For example, some pathogens
12 use unique nutrients, such as ethanolamine, that commensal symbionts cannot use (Thiennimitr et al.,
13 2011). Likewise, relocation of the living niche provides an escape from the nutritional competition. For
14 example, *Citrobacter rodentium*, a mouse pathogen used to model human infections with
15 enteropathogenic *E. coli* (EPEC) and enterohemorrhagic *E. coli* (EHEC), resides on the intestinal
16 epithelial surface by expressing the locus of enterocyte effacement (LEE) virulence factor. In this new
17 niche, *C. rodentium* can acquire specific nutrients not accessible to commensal symbionts residing in the
18 luminal niche (Kamada et al., 2012). However, unlike *C. rodentium* or other enteropathogens, commensal
19 pathobionts, such as AIEC, lack the LEE virulence factors, and therefore the niche relocation is rarely
20 executed in the steady-state (i.e., intact gut microbiota and mucus barrier). These pathobionts are,
21 therefore, not classified as obligate pathogens, but rather as opportunistic pathogens. In other words,
22 pathobionts have a poor ability to proliferate and establish infection in the healthy hosts. Instead,
23 pathobionts bloom only in conditions that compromise the host's defenses, including the colonization
24 resistance by the healthy gut microbiota. In this context, we found that mucolytic bacteria, such as *A.*
25 *muciniphila*, can serve as metabolic supporters for AIEC in the gut. Although *A. muciniphila* may not
26 directly promote the growth of AIEC, *A. muciniphila* licenses AIEC to acquire alternative nutrients by
27 facilitating its niche relocation.

28
29 Some pathogens, like AIEC, which can reside in the epithelial niche, can obtain nutrients from
30 infected host cells for replication. For example, EPEC exploits nutrients from infected host cells by using
31 injectisome components, which enable the pathogen to thrive in competitive niches (Pal et al., 2019). As
32 AIEC strains lack injectisome components, it is plausible that AIEC exploits a distinct mechanism to
33 extract host-derived nutrients when associated with the epithelial niche. In this regard, AIEC may invade
34 the colonic epithelium to acquire nutrients from the host cells rather than extracting nutrients from the cell
35 surface, as cellular invasion is a unique pathogenic feature of AIEC strains compared to other pathogenic
36 *E. coli* strains (Glasser et al., 2001; Lapaquette et al., 2010). Further research is required to identify the

1 mechanisms by which AIEC exploits host-derived nutrients. Our present study shows that AIEC uses L-
2 serine pooled in the host epithelium. This notion was supported by the upregulation of L-serine utilization
3 genes in AIEC when associated with the IECs, along with the reduced free L-serine concentration in the
4 IECs. Moreover, the growth promotion of AIEC due to the AIEC–IEC interaction does not occur if the
5 AIEC strain is incapable of utilizing L-serine (i.e., Δ T5 mutant AIEC LF82). Along with the aforementioned
6 critical roles of L-serine that enable AIEC to adapt to the inflammatory environment, our results confirm
7 that L-serine is a major nutrient extracted from the host cells by AIEC in this setting. However, AIEC may
8 extract and use other host-derived nutrients in addition to L-serine. In this context, several pathogens
9 exploit host glycan metabolites as nutrient sources. For example, *Salmonella enterica* serovar
10 Typhimurium and *Clostridioides difficile* use sialic acid liberated from host mucus glycans by *Bacteroides*
11 *thetaiotaomicron* (Ng et al., 2013). EHEC uses fucose, also liberated from host glycans by *B.*
12 *thetaiotaomicron*, for the regulation of virulence factor expression and colonization in the gut (Pacheco
13 et al., 2012). AIEC strains can also use fucose as a nutrient source through propanediol dehydratase
14 (Viladomiu et al., 2017; Viladomiu et al., 2021). Consistent with this notion, AIEC upregulated genes
15 related to the metabolism of other possible host-derived nutrients (e.g., mannose, *N*-acetylglucosamine)
16 when associated with IECs. These other metabolites may compensate for the growth of AIEC, at least to
17 some extent, in the absence of L-serine. Nevertheless, the studies by us and others as described suggest
18 that L-serine plays a major role among diet- and host-derived nutrients accessible to AIEC in regulating
19 its fitness.

20

21 Considered in their entirety, our results demonstrate that the pathogenic capacity of commensal
22 pathobionts, such as AIEC, is context dependent. In the steady-state gut, pathobionts may behave as
23 nonpathogenic commensals. Pathobionts may be detrimental only when metabolic supporters are
24 present. Notably, the metabolic supporters, such as mucolytic bacteria, per se are not detrimental. Also,
25 the balance of luminal nutrients, regulated by diet, is essential to elicit the interaction between pathobionts
26 and metabolic supporters. Therefore, the complex pathobiont–symbiont interactions dictate the success
27 of dietary interventions. Hence, a personalized dietary intervention adapted to the composition of an
28 individual's gut microbiota is required to treat IBD effectively.

29

1 **LIMITATIONS OF THE STUDY**

2 Although our study provides a comprehensive understanding of the diet–microbe interactions in the
3 inflamed gut, several limitations deserve mention. First, regarding clinical relevance, we need to
4 investigate the interaction between AIEC and other mucolytic bacteria, such as *Ruminococcus gnavus*,
5 which is reported to be a pathobiont involved in the pathogenesis of IBD. As some clinical studies have
6 shown the reduced abundance of *A. muciniphila* in IBD patients, it is possible that other mucolytic bacteria
7 also license AIEC to colonize the epithelial niche in human IBD. Second, we show that AIEC exploits L-
8 serine provided by host IECs; however, the mechanism by which L-serine is required for the colonization
9 and replication of AIEC in IECs remains unclear. AIEC preferentially consumes L-serine in the gut, and
10 moreover, L-serine is required to adapt to the inflammatory microenvironment. Therefore, it is conceivable
11 that AIEC uses L-serine for the stress response and the energy source for bacterial growth. Elucidation
12 of these limitations will advance the understanding of diet–microbe interactions during gut inflammation.
13

1 RESOURCE AVAILABILITY

2 Lead Contact

3 Further information and requests for resources and reagents should be directed to and fulfilled by the
4 Lead Contact, Nobuhiko Kamada (nkamada@umich.edu).

6 Data and Code Availability

7 The accession number for the 16S rRNA MiSeq data and bacterial RNA sequence data reported in this
8 paper is PRJNA763203.

10 EXPERIMENTAL MODEL AND SUBJECT DETAILS

11 Human data

12 Metagenomics, metatranscriptomics, and metabolomics data were downloaded from the public resource,
13 the second phase of the Integrative Human Microbiome Project (HMP2 or iHMP) – the Inflammatory
14 Bowel Disease Multi'omics Database (<https://ibdmdb.org/>). The description and collection of samples,
15 and the data preprocessing are explained in a previous study (Lloyd-Price et al., 2019). The samples
16 included in the current analysis are described in **Figure 1A**.

18 Animal

19 SPF C57BL/6 mice were housed by the Unit for Laboratory Animal Medicine at the University of Michigan.
20 GF Swiss Webster mice were obtained from the Germ-Free Mouse Facility at the University of Michigan.
21 GF mice were housed in flexible film isolators, and their germ-free status was confirmed weekly by
22 aerobic and anaerobic culture. Female and male mice, age 6 – 12 wk, were used in all experiments. Mice
23 were fed either a control amino acid–based diet (Ctrl., TD.130595) or an L-serine deficient diet (Δ Ser,
24 TD.140546), which had been used previously (Kitamoto et al., 2020; Maddocks et al., 2013). The custom
25 diets were manufactured by Envigo (Madison, WI) and sterilized by gamma irradiation. All animal studies
26 were performed in accordance with protocols reviewed and approved by the Institutional Animal Care
27 and Use Committee at the University of Michigan.

29 Cell culture

30 T84 cells derived from a human colorectal carcinoma cell line were purchased from ATCC (Gaithersburg,
31 MD) and cultured in Ham's F-12 nutrient mixture + DMEM (1:1) supplemented with 10% FBS and an
32 antibiotic solution (penicillin-streptomycin). The human stem cell–derived colonoid line was cultured as
33 described in the protocol from the Translational Tissue Modeling Laboratory at the University of Michigan
34 (<https://www.umichttml.org>). Histologically normal colon tissue from subjects (donors 81, 84, and 88) in
35 our previous studies was used for the colonoid culture (Dame et al., 2018; Tsai et al., 2018). The collection
36 and use of human colonic tissue for the colonoids were approved by the Institutional Review Boards

1 (IRBMED) at the University of Michigan. The experiment was conducted according to the principles stated
2 in the Declaration of Helsinki.

3

4 **METHOD DETAILS**

5 **Histology**

6 The colon tissues were quickly removed and immediately preserved overnight in 4% paraformaldehyde
7 for regular histology assessment or in Carnoy's fixative (60% dry methanol, 30% chloroform, 10% glacial
8 acetic acid) for mucus barrier evaluation. The preserved colon tissues were then incubated in 70%
9 ethanol or dry methanol, respectively, and processed into paraffin-embedded tissue sections (4–5 μm)
10 and stained with HE for histological assessment. Histological inflammation was scored at the In-Vivo
11 Animal Core in the Unit for Laboratory Animal Medicine at the University of Michigan. A veterinary
12 pathologist performed a blind evaluation of the histological scores. Inflammation and epithelial loss were
13 assessed for severity based on the most severe lesion in each section (i.e., 0, none; 1, mild; 2, moderate;
14 3, severe; 4, marked). Lesion extent was assessed as the percent of the section affected (0, 0%; 1, 1%–
15 25%; 2, 26%–50%; 3, 51%–75%; 4, 76%–100%). The extent and severity scores for inflammation and
16 epithelial cell loss were multiplied to give a total score for each parameter (range 0–16). The total scores
17 for each parameter were summed to give a total colitis score (range 0–32).

18

19 **DNA extraction, qPCR, and 16S rRNA sequencing**

20 Fecal DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen, Germantown, MD), according
21 to a procedure used in a previous study (Nagao-Kitamoto et al., 2016). In the gnotobiotic experiments,
22 fecal DNA was isolated by phenol:chloroform:isoamyl alcohol, as previously described (Steimle et al.,
23 2021). Briefly, 500 μL buffer A (200 mM NaCl, 200 mM Tris, 20 mM EDTA), 210 μL 20% SDS (filter
24 sterilized), and 500 μL phenol:chloroform:isoamyl alcohol (125:24:1, pH 8.0, Thermo Fischer Scientific,
25 Waltham, MA) were added to the cecal content. The mixture was subjected to bead beating for 3 min at
26 4°C and centrifuged at 4°C (17,000g for 3 min). The aqueous phase was recovered, and 500 μL
27 phenol:chloroform:isoamyl alcohol (pH 8.0) was added. After mixing with a vortex mixer, the mixture was
28 centrifuged again at 4°C (17,000g for 3 min). The aqueous phase was recovered and 500 μL of
29 chloroform was added and mixed by inversion. After centrifuging (17,000g) for 3 min, the aqueous phase
30 was transferred to new tubes, and 60 μL 3 M sodium acetate (pH 5.2) and 600 μL isopropanol were
31 added. After incubation for 60 min at -20°C, the mixture was centrifuged at 4°C (13,000 rpm for 20 min).
32 The pellet was washed with 70% ethanol, and resuspended in nuclease-free water. DNA was further
33 cleaned using the DNeasy Blood and Tissue Kit (Qiagen). qPCR was performed using a Radiant SYBR
34 Green Lo-ROX qPCR Kit (Alkali Scientific, Fort Lauderdale, FL). To eliminate the inhibitory effect of
35 dextran sodium sulfate (DSS) on qPCR, spermine was added to the PCR (Krych et al., 2018). The relative
36 expression of the target bacteria was calculated using universal 16S primers as a reference. In the

1 gnotobiotic experiments, the relative abundance of bacteria was calculated using the standard curves
2 obtained from the monoculture of each strain (Steimle et al., 2021). The primer sets used for amplification
3 are listed in **Table S1**. For the 16S rRNA sequencing, PCR and library preparation were performed at the
4 Microbiome Core at the University of Michigan. The V4 region of the 16S rRNA-encoding gene was
5 amplified from extracted DNA using the barcoded dual-index primers, as reported previously (Kozich et
6 al., 2013). Samples were amplified, normalized, and sequenced on the MiSeq system. Raw sequences
7 were analyzed using mothur (v1.33.3). Operational taxonomic units (OTUs) (>97% identity) were curated
8 and converted to relative abundance using mothur. We performed LEfSe to identify significant
9 differentially abundant OTUs.

11 **Measurement of the thickness of the colonic mucus layer**

12 To measure the thickness of the colonic inner mucus layer, the colonic sections were stained with alcian
13 blue/periodic acid–Schiff (AB/PAS) according to the following protocol: 1) deparaffinize and hydrate in
14 distilled water, 2) 3% acetic acid for 3 min, 3) AB solution for 15 min, 4) wash in running tap water for 2
15 min, 4) periodic acid solution for 5 min, 5) rinse with distilled water, 6) Schiff reagent for 15 min, 7) wash
16 in running tap water for 5 min, 8) Gill hematoxylin solution for 90 sec, 9) wash in running tap water for 5
17 min, 10) dehydrate and clear in xylene, 11) cover with a coverslip. We used the images captured of all
18 the available fecal masses of each mouse for quantification, although this number was variable, and
19 generally, the colitic mice had fewer colonic fecal masses. The thickness of the mucus layer in the colonic
20 sections was measured using ImageJ.

22 **FISH and immunofluorescence staining**

23 FISH and MUC2 immunofluorescence staining were performed according to a previous study, with slight
24 modifications (Johansson and Hansson, 2012). Briefly, paraffin-embedded colon sections were
25 deparaffinized and hydrated. Sections were then incubated with 2 µg Alexa555-conjugated EUB338 (5'-
26 GCTGCCTCCCGTAGGAGT-3') in 200 µL hybridization buffer (20 mM Tris-HCl, 0.9 M NaCl, 0.1% (w/v)
27 SDS) at 50°C. After overnight incubation, sections were rinsed in wash buffer (20 mM Tris-HCl, 0.9 M
28 NaCl) at 50°C for 15 min. Sections were blocked with 1% BSA in PBS at room temperature for 1 h and
29 then incubated with anti-MUC2 antibody (H-300; Santa Cruz Biotechnology, Dallas, TX) at 4°C for 6 h.
30 After washing with PBS, sections were incubated with Alexa 488-conjugated rabbit polyclonal antibody
31 (Invitrogen, Thermo Fisher Scientific, Waltham, MA) and DAPI at room temperature for 1 h. To reduce
32 autofluorescence, the sections were treated with an autofluorescence quenching kit (Vector Laboratories,
33 Burlingame, CA), according to the manufacturer's instruction. The slides were stored overnight, in the
34 dark, at room temperature, and then visualized using the Nikon Eclipse TE2000-S inverted microscope
35 (Nikon USA, Melville, NY). For the in vitro experiment, immunofluorescence staining of MUC2 and *E. coli*
36 was performed as previously described, with slight modifications (Liu et al., 2020). Briefly, the human-

1 derived colonoid monolayer (HCM) was fixed with Carnoy's solution (90% dry methanol and 10% glacial
2 acetic acid), washed 2 times with PBS, permeabilized with 0.1% Triton-X for 10 min, and blocked with
3 1% BSA/PBS for 30 min. Cells were then incubated with MUC2 antibody (H-300; Santa Cruz
4 Biotechnology) and anti-*E. coli* LPS antibody (2D7/1; Abcam, Waltham, MA) in 1% BSA/PBS overnight
5 at 4°C. The cells were then washed with PBS twice for 5 min followed by incubation with Alexa Fluor
6 488-conjugated goat anti-rabbit antibody (Invitrogen), Alexa Fluor 555-conjugated goat anti-mouse
7 antibody (Invitrogen), and DAPI for 1 h at room temperature. Stained cells were analyzed using a Nikon
8 A1 confocal microscope.

9

10 **Intestinal permeability assay**

11 Intestinal permeability assay was performed using FITC-dextran, as described previously (Chassaing et
12 al., 2014). Briefly, mice were deprived of food for 4 h and then gavaged with 0.6 mg/g body weight 4 kDa
13 FITC-dextran (FD4, Sigma-Aldrich St. Louis, MO). Blood was collected after 4 h, and fluorescence
14 intensity was measured (excitation, 485 nm; emission, 520 nm). FITC-dextran concentrations were
15 determined using a standard curve generated by the serial dilution of FITC-dextran.

16

17 **Gnotobiotic experiments**

18 GF Swiss Webster mice were colonized by a consortium of human synthetic microbiota, as reported
19 previously (Desai et al., 2016), with a few modifications. The composition of the bacteria consortium is
20 shown in **Figure 6A and Figure S3A**. Bacteria were anaerobically (i.e., 85% N₂, 10% H₂, 5% CO₂)
21 cultured in their respective media at 37°C with final absorbance (600 nm) readings ranging from about
22 1.0. *Bacteroides ovatus* (DSMZ 1896), *B. uniformis* (ATCC 8492), *Clostridium symbiosum* (DSMZ 934),
23 *Collinsella aerofaciens* (DSMZ 3979), and *E. coli* (ATCC HS and CD patient-derived LF82) were cultured
24 in TYG medium (Moore, 1977). Modified chopped meat medium (Hehemann et al., 2012) was used to
25 culture *A. muciniphila* (DSMZ 22959) and *Eubacterium rectale* (DSMZ 17629). *Roseburia intestinalis*
26 (DSMZ 14610), *Faecalibacterium prausnitzii* (DSMZ 17677), and *Marvinbryantia formatexigens* (DSMZ
27 14469) were cultured in YCFA medium (Ze et al., 2012). *Desulfovibrio piger* (ATCC 29098) was cultured
28 in ATCC 1249 medium. Bacterial cultures were mixed in equal volumes, and the mice were orally gavaged
29 with 0.2 mL of this mixture. After a 14-day reconstitution, the mice were fed a sterilized custom diet and
30 treated with DSS.

31

32 ***E. coli* infection in vivo and in vitro**

33 For *E. coli* infection in vivo, mice were infected with each *E. coli* strain (1 × 10⁹ colony forming units
34 (CFU)/mouse). To assess *E. coli* colonization, homogenates of feces and colon tissues were cultured on
35 LB agar plates with ampicillin or streptomycin. The number of viable bacteria was estimated by plate
36 counting the number of CFUs. In the in vitro experiments, T84 cells or the HCM were infected with *E. coli*

1 at an MOI = 1–10 (2×10^5 – 2×10^6 CFU/well) as described in the respective **Figures 5, 7, and S4**. After
2 infection, the cells were centrifuged at 1,000g for 10 min at 24°C and maintained at 37°C. In the bacterial
3 adhesion assay, cells were washed three times with PBS and then lysed with 0.1% Triton X-100 (Sigma-
4 Aldrich) in deionized water. In the bacterial invasion assay, cells were infected with *E. coli* for 1–3 h and
5 then cultured with gentamycin (100 µg/mL) to kill extracellular *E. coli*. After incubation, the cells were
6 washed 3 times with PBS and then lysed with 0.1% Triton X-100 in deionized water. Lysed cells were
7 diluted and plated on LB agar plates to determine the number of CFUs corresponding to the total number
8 of cell-associated bacteria.

9 10 **Coculture of anaerobic bacteria with primary human colon monolayers**

11 The human-derived colonoids were provided by the Translational Tissue Modeling Laboratory at the
12 University of Michigan. To generate the monolayers, the three-dimensional human colonoids were
13 dissociated into a single-cell suspension and plated on collagen IV (Sigma-Aldrich)-coated transwell
14 inserts (0.4 µm pore size, 0.33 cm², polyester [PET], Costar, Corning, Tewksbury, MA) in a 24-well plate.
15 After 24 h, the growth medium was replaced with differentiation medium (Watson et al., 2014).
16 Differentiation was completed in a 5% O₂, 5% CO₂, balanced N₂ environment. The medium was refreshed
17 every 48 h for 6 days. Transepithelial electrical resistance (TEER) was determined to be present in an
18 intact monolayer (>400 Ω/cm²), which is suitable for an anaerobic coculture system. TEER was recorded
19 using an electrical volt/ohm meter (World Precision Instruments, Sarasota, FL). The transwell plates were
20 set in the apical chambers (Coy Laboratory Products, Grass Lake, MI) of an anaerobic chamber (5% CO₂,
21 balance N₂ environment), and cultured in an anaerobic coculture system as shown in **Figure 6A** (Lauder
22 et al., 2020). Briefly, setting up the apical chamber, a 24-well gas-permeable plate was placed on the
23 base and sealed in place using double-sided adhesive tape. The entire apparatus was placed in an
24 anaerobic chamber (90% N₂, 5% H₂, 5% CO₂) to allow the growth of anaerobic bacteria in the apical
25 wells. 5.0% O₂ was pumped from an external tank through the base of the plate to supply oxygen to the
26 basolateral side of the monolayer. The basal compartment was maintained in a 5% O₂, 5% CO₂, balance
27 N₂ environment, whereas the apical chamber was maintained in a 5% CO₂, balance N₂ environment. The
28 colonoid monolayer was cultured with differentiation medium in the basolateral wells and minimal
29 coculture medium in the apical wells. To evaluate the impact of *A. muciniphila* on the integrity of the
30 mucus layer and the adhesion of AIEC, the apical well was infected with *A. muciniphila* (4×10^4 CFU/well)
31 for 18 h, and then with LF82 (4×10^3 CFU/well) for 3 h. LF82 adhesion was assessed as described.

32 33 **Bacterial RNA-sequencing**

34 Bacterial RNA was isolated with a bacterial RNA isolation kit (Omega Bio-tek, Norcross, GA), according
35 to the manufacturer's protocol. Isolated RNA was treated with DNase (Thermo Fisher Scientific) and then
36 cleaned with an RNeasy Mini Kit (QIAGEN). Library preparation and sequencing of the RNA-seq libraries

1 were performed in the Advanced Genomics Core at the University of Michigan. Briefly, RNA was
2 assessed for quality using the Agilent TapeStation system (Agilent, Santa Clara, CA). Samples were
3 prepared using the New England BioLabs (Ipswich, MA) NEBNext Ultra II Directional RNA Library Prep
4 Kit for Illumina, the NEBNext rRNA Depletion Kit (Bacteria), the NEBNext rRNA Depletion Kit
5 (Human/Mouse/Rat), and the NEBNext Multiplex Oligos for Illumina (Unique Dual Index for Primer Pairs),
6 where 145 ng total RNA was ribosomal depleted using the human/mouse/rat and bacteria rRNA depletion
7 modules. The rRNA-depleted RNA was then fragmented for 7–10 min determined by the RIN (RNA
8 Integrity Number) of input RNA as per protocol and copied into first-strand cDNA using reverse
9 transcriptase and dUTP mix. The samples underwent end repair and dA-tailing, followed by ligation of
10 the NEBNext adapters. The products were purified and enriched by PCR to create the final cDNA libraries,
11 which were checked for quality and quantity by the Agilent TapeStation system and Qubit (Thermo Fisher
12 Scientific). The samples were pooled and sequenced on the Illumina NovaSeq 6000 S4 paired-end 150
13 bp, according to the manufacturer's recommended protocols (Illumina, San Diego, CA. bcl2fastq2
14 Conversion Software (Illumina) was used to generate de-multiplexed Fastq files. Paired-end reads were
15 mapped on LF82 genomic sequence CU651637 by bowtie2 and reads of individual LFL82 genes were
16 counted by HTSeq as described (Kitamoto *et al.*, 2020). Human transcripts were mapped on human
17 cDNA sequences GRCg38 and counted by Salmon (<https://pubmed.ncbi.nlm.nih.gov/28263959/>). For
18 functional GO enrichment analysis, over-represented and under-represented bacterial genes were
19 identified by LEfSe and then analyzed using the Gene Ontology Resource (<http://geneontology.org>)

21 **QUANTIFICATION AND STATISTICAL ANALYSIS**

22 Statistical analyses were performed using GraphPad Prism 9.3.0 (GraphPad Software San Diego, CA).
23 The numbers of animals used for individual experiments, details of the statistical tests used, and pooled
24 values for several biological replicates are indicated in the respective figure legends. Differences between
25 the two groups were evaluated using the two-tailed Student *t* test or the Mann–Whitney U test. 1-way
26 ANOVA or the Kruskal–Wallis test followed by the Tukey correction or the Dunn test was performed for
27 the comparison of more than 3 groups. Differences of $p < 0.05$ were considered significant. Statistically
28 significant differences are shown with asterisks as follows: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, whereas
29 N.S. indicates comparisons that are not significant.

1 **Acknowledgements**

2 The authors wish to thank the University of Michigan Center for Gastrointestinal Research (NIH
3 5P30DK034933), and the Host Microbiome Initiative, the Germ-Free Mouse Facility, the In-Vivo Animal
4 Core, the Advanced Genomics Core, the School of Dentistry Histology Core, the Rogel Cancer Center
5 Tissue & Molecular Pathology Shared Resource, the Microscopy Core, the Metabolomics Core, and the
6 Translational Tissue Modeling Laboratory, all at the University of Michigan. We also thank Peter Kuffa,
7 Yadong Mao, and Ingrid L. Bergin for experimental assistance and Eric C Martens for providing bacterial
8 strains of SM. This work was supported by National Institutes of Health grants DK110146, DK108901,
9 DK125087, DK119219, and AI142047 (to N.K.), the Kenneth Rainin Foundation Innovator Award and
10 Synergy Award (to N.K.), a JSPS Postdoctoral Fellowship for Research Abroad (to K.S., S.K., and H.N.-
11 K.), the Uehara Memorial Foundation Postdoctoral Fellowship Award (to K.S., and S.K.), and the Crohn's
12 and Colitis Foundation (to K.S., H.N.-K., and N.K.), and the Office of the Assistant Secretary of Defense
13 for Health Affairs endorsed by the Department of Defense through the Peer-Reviewed Cancer Research
14 Program under Award No. W81XWH2010547 (to S.K.).

15

16 **Author contributions**

17 K.S and N.K. conceived and designed the experiments. K.S. conducted most of the experiments with
18 help from S.K., P.S., H.N-K., A.R., J.I., and M.O.. M.G.G. and N.I. performed 16S rRNA sequencing and
19 RNA sequencing analysis. P.S., C.K.M., M.H., A.N., and J.G. contributed to the establishment of the
20 colonoid culture and anaerobic coculture experiment. S.B., J.Y.K., C.J.A., N.B., A.N., and J.G. provided
21 advice and constructive discussion of the results. K.S. and N.K. analyzed the data. K.S. and N.K. wrote
22 the manuscript with contributions from all authors.

23

24 **Competing interests**

25 The authors declare no competing interests.

26

1 **Reference**

- 2 Ananthakrishnan, A.N. (2015). Epidemiology and risk factors for IBD. *Nat Rev Gastroenterol Hepatol* 12,
3 205-217. 10.1038/nrgastro.2015.34.
- 4 Becattini, S., Sorbara, M.T., Kim, S.G., Littmann, E.L., Dong, Q., Walsh, G., Wright, R., Amoretti, L.,
5 Fontana, E., Hohl, T.M., and Pamer, E.G. (2021). Rapid transcriptional and metabolic adaptation of
6 intestinal microbes to host immune activation. *Cell Host Microbe*. 10.1016/j.chom.2021.01.003.
- 7 Caballero-Flores, G., Pickard, J.M., Fukuda, S., Inohara, N., and Nunez, G. (2020). An Enteric Pathogen
8 Subverts Colonization Resistance by Evading Competition for Amino Acids in the Gut. *Cell Host*
9 *Microbe* 28, 526-533 e525. 10.1016/j.chom.2020.06.018.
- 10 Cameron, E.A., and Sperandio, V. (2015). Frenemies: Signaling and Nutritional Integration in Pathogen-
11 Microbiota-Host Interactions. *Cell Host Microbe* 18, 275-284. 10.1016/j.chom.2015.08.007.
- 12 Cani, P.D., and de Vos, W.M. (2017). Next-Generation Beneficial Microbes: The Case of *Akkermansia*
13 *muciniphila*. *Front Microbiol* 8, 1765. 10.3389/fmicb.2017.01765.
- 14 Carvalho, F.A., Barnich, N., Sivignon, A., Darcha, C., Chan, C.H., Stanners, C.P., and Darfeuille-Michaud,
15 A. (2009). Crohn's disease adherent-invasive *Escherichia coli* colonize and induce strong gut
16 inflammation in transgenic mice expressing human CEACAM. *J Exp Med* 206, 2179-2189.
17 10.1084/jem.20090741.
- 18 Chassaing, B., Aitken, J.D., Malleshappa, M., and Vijay-Kumar, M. (2014). Dextran sulfate sodium (DSS)-
19 induced colitis in mice. *Curr Protoc Immunol* 104, 15 25 11-15 25 14.
20 10.1002/0471142735.im1525s104.
- 21 Dame, M.K., Attili, D., McClintock, S.D., Dedhia, P.H., Ouillette, P., Hardt, O., Chin, A.M., Xue, X., Laliberte,
22 J., Katz, E.L., et al. (2018). Identification, isolation and characterization of human LGR5-positive
23 colon adenoma cells. *Development* 145. 10.1242/dev.153049.
- 24 Dao, M.C., Everard, A., Aron-Wisnewsky, J., Sokolovska, N., Prifti, E., Verger, E.O., Kayser, B.D.,
25 Levenez, F., Chilloux, J., Hoyles, L., et al. (2016). *Akkermansia muciniphila* and improved metabolic
26 health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology.
27 *Gut* 65, 426-436. 10.1136/gutjnl-2014-308778.
- 28 Derrien, M., Vaughan, E.E., Plugge, C.M., and de Vos, W.M. (2004). *Akkermansia muciniphila* gen. nov.,
29 sp. nov., a human intestinal mucin-degrading bacterium. *Int J Syst Evol Microbiol* 54, 1469-1476.
30 10.1099/ijs.0.02873-0.
- 31 Desai, M.S., Seekatz, A.M., Koropatkin, N.M., Kamada, N., Hickey, C.A., Wolter, M., Pudlo, N.A.,
32 Kitamoto, S., Terrapon, N., Muller, A., et al. (2016). A Dietary Fiber-Deprived Gut Microbiota
33 Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. *Cell* 167, 1339-1353
34 e1321. 10.1016/j.cell.2016.10.043.
- 35 Eisenreich, W., Dandekar, T., Heesemann, J., and Goebel, W. (2010). Carbon metabolism of intracellular
36 bacterial pathogens and possible links to virulence. *Nat Rev Microbiol* 8, 401-412.

- 1 10.1038/nrmicro2351.
- 2 Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J.P., Druart, C., Bindels, L.B., Guiot, Y., Derrien, M.,
3 Muccioli, G.G., Delzenne, N.M., et al. (2013). Cross-talk between *Akkermansia muciniphila* and
4 intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A* *110*, 9066-9071.
5 10.1073/pnas.1219451110.
- 6 Glasser, A.L., Boudeau, J., Barnich, N., Perruchot, M.H., Colombel, J.F., and Darfeuille-Michaud, A.
7 (2001). Adherent invasive *Escherichia coli* strains from patients with Crohn's disease survive and
8 replicate within macrophages without inducing host cell death. *Infect Immun* *69*, 5529-5537.
9 10.1128/iai.69.9.5529-5537.2001.
- 10 Guo, Y., Kitamoto, S., and Kamada, N. (2020). Microbial adaptation to the healthy and inflamed gut
11 environments. *Gut Microbes* *12*, 1857505. 10.1080/19490976.2020.1857505.
- 12 Hehemann, J.H., Kelly, A.G., Pudlo, N.A., Martens, E.C., and Boraston, A.B. (2012). Bacteria of the
13 human gut microbiome catabolize red seaweed glycans with carbohydrate-active enzyme updates
14 from extrinsic microbes. *Proc Natl Acad Sci U S A* *109*, 19786-19791. 10.1073/pnas.1211002109.
- 15 Ilott, N.E., Bollrath, J., Danne, C., Schiering, C., Shale, M., Adelman, K., Krausgruber, T., Heger, A.,
16 Sims, D., and Powrie, F. (2016). Defining the microbial transcriptional response to colitis through
17 integrated host and microbiome profiling. *ISME J* *10*, 2389-2404. 10.1038/ismej.2016.40.
- 18 Imai, J., Kitamoto, S., Sugihara, K., Nagao-Kitamoto, H., Hayashi, A., Morhardt, T.L., Kuffa, P., Higgins,
19 P.D.R., Barnich, N., and Kamada, N. (2019). Flagellin-mediated activation of IL-33-ST2 signaling by
20 a pathobiont promotes intestinal fibrosis. *Mucosal Immunol* *12*, 632-643. 10.1038/s41385-019-0138-
21 4.
- 22 Johansson, M.E., Gustafsson, J.K., Holmen-Larsson, J., Jabbar, K.S., Xia, L., Xu, H., Ghishan, F.K.,
23 Carvalho, F.A., Gewirtz, A.T., Sjovall, H., and Hansson, G.C. (2014). Bacteria penetrate the normally
24 impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis.
25 *Gut* *63*, 281-291. 10.1136/gutjnl-2012-303207.
- 26 Johansson, M.E., and Hansson, G.C. (2012). Preservation of mucus in histological sections,
27 immunostaining of mucins in fixed tissue, and localization of bacteria with FISH. *Methods Mol Biol*
28 *842*, 229-235. 10.1007/978-1-61779-513-8_13.
- 29 Johansson, M.E., Phillipson, M., Petersson, J., Velcich, A., Holm, L., and Hansson, G.C. (2008). The
30 inner of the two *Muc2* mucin-dependent mucus layers in colon is devoid of bacteria. *Proc Natl Acad*
31 *Sci U S A* *105*, 15064-15069. 10.1073/pnas.0803124105.
- 32 Kamada, N., Kim, Y.G., Sham, H.P., Vallance, B.A., Puente, J.L., Martens, E.C., and Nunez, G. (2012).
33 Regulated virulence controls the ability of a pathogen to compete with the gut microbiota. *Science*
34 *336*, 1325-1329. 10.1126/science.1222195.
- 35 Kitamoto, S., Alteri, C.J., Rodrigues, M., Nagao-Kitamoto, H., Sugihara, K., Himpl, S.D., Bazzi, M.,
36 Miyoshi, M., Nishioka, T., Hayashi, A., et al. (2020). Dietary L-serine confers a competitive fitness

- 1 advantage to Enterobacteriaceae in the inflamed gut. *Nat Microbiol* 5, 116-125. 10.1038/s41564-
2 019-0591-6.
- 3 Kozich, J.J., Westcott, S.L., Baxter, N.T., Highlander, S.K., and Schloss, P.D. (2013). Development of a
4 dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the
5 MiSeq Illumina sequencing platform. *Appl Environ Microbiol* 79, 5112-5120. 10.1128/AEM.01043-13.
- 6 Krych, L., Kot, W., Bendtsen, K.M.B., Hansen, A.K., Vogensen, F.K., and Nielsen, D.S. (2018). Have you
7 tried spermine? A rapid and cost-effective method to eliminate dextran sodium sulfate inhibition of
8 PCR and RT-PCR. *J Microbiol Methods* 144, 1-7. 10.1016/j.mimet.2017.10.015.
- 9 Lambert, K., Pappas, D., Miglioretto, C., Javadpour, A., Reveley, H., Frank, L., Grimm, M.C., Samocha-
10 Bonet, D., and Hold, G.L. (2021). Systematic review with meta-analysis: dietary intake in adults with
11 inflammatory bowel disease. *Aliment Pharmacol Ther* 54, 742-754. 10.1111/apt.16549.
- 12 Lapaquette, P., Glasser, A.L., Huett, A., Xavier, R.J., and Darfeuille-Michaud, A. (2010). Crohn's disease-
13 associated adherent-invasive *E. coli* are selectively favoured by impaired autophagy to replicate
14 intracellularly. *Cell Microbiol* 12, 99-113. 10.1111/j.1462-5822.2009.01381.x.
- 15 Lauder, E., Kim, K., Schmidt, T.M., and Golob, J.L. (2020). Organoid-derived adult human colonic
16 epithelium responds to co-culture with a probiotic strain of *Bifidobacterium longum*. *BioRxiv*.
17 10.1101/2020.07.16.207852.
- 18 Liu, L., Saitz-Rojas, W., Smith, R., Gonyar, L., In, J.G., Kovbasnjuk, O., Zachos, N.C., Donowitz, M.,
19 Nataro, J.P., and Ruiz-Perez, F. (2020). Mucus layer modeling of human colonoids during infection
20 with enteroaggregative *E. coli*. *Sci Rep* 10, 10533. 10.1038/s41598-020-67104-4.
- 21 Lloyd-Price, J., Arze, C., Ananthakrishnan, A.N., Schirmer, M., Avila-Pacheco, J., Poon, T.W., Andrews,
22 E., Ajami, N.J., Bonham, K.S., Brislawn, C.J., et al. (2019). Multi-omics of the gut microbial
23 ecosystem in inflammatory bowel diseases. *Nature* 569, 655-662. 10.1038/s41586-019-1237-9.
- 24 Ma, E.H., Bantug, G., Griss, T., Condotta, S., Johnson, R.M., Samborska, B., Mainolfi, N., Suri, V., Guak,
25 H., Balmer, M.L., et al. (2017). Serine Is an Essential Metabolite for Effector T Cell Expansion. *Cell*
26 *Metab* 25, 345-357. 10.1016/j.cmet.2016.12.011.
- 27 Maddocks, O.D., Berkers, C.R., Mason, S.M., Zheng, L., Blyth, K., Gottlieb, E., and Vousden, K.H. (2013).
28 Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. *Nature*
29 493, 542-546. 10.1038/nature11743.
- 30 Maddocks, O.D.K., Athineos, D., Cheung, E.C., Lee, P., Zhang, T., van den Broek, N.J.F., Mackay, G.M.,
31 Labuschagne, C.F., Gay, D., Kruiswijk, F., et al. (2017). Modulating the therapeutic response of
32 tumours to dietary serine and glycine starvation. *Nature* 544, 372-376. 10.1038/nature22056.
- 33 Matthews, R., and Neidhardt, F. (1989). Elevated serine catabolism is associated with the heat shock
34 response in *Escherichia coli*. *J Bacteriol* 171, 2619-2625. 10.1128/jb.171.5.2619-2625.1989.
- 35 Moore, E.C.L.H.W. (1977). *Anaerobe laboratory manual*, 4th edition Edition (Blacksburg).
- 36 Morgan XC, T.T., Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper

- 1 SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C (2012). Dysfunction of the
2 intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biol* 16 (13), R79.
3 10.1186/gb-2012-13-9-r79.
- 4 Nadalian, B., Yadegar, A., Hourri, H., Olfatifar, M., Shahrokh, S., Asadzadeh Aghdaei, H., Suzuki, H., and
5 Zali, M.R. (2021). Prevalence of the pathobiont adherent-invasive *Escherichia coli* and inflammatory
6 bowel disease: a systematic review and meta-analysis. *J Gastroenterol Hepatol* 36, 852-863.
7 10.1111/jgh.15260.
- 8 Nagao-Kitamoto, H., Shreiner, A.B., Gilliland, M.G., 3rd, Kitamoto, S., Ishii, C., Hirayama, A., Kuffa, P.,
9 El-Zaatari, M., Grasberger, H., Seekatz, A.M., et al. (2016). Functional Characterization of
10 Inflammatory Bowel Disease-Associated Gut Dysbiosis in Gnotobiotic Mice. *Cell Mol Gastroenterol*
11 *Hepatol* 2, 468-481. 10.1016/j.jcmgh.2016.02.003.
- 12 Newman, A.C., and Maddocks, O.D.K. (2017). Serine and Functional Metabolites in Cancer. *Trends Cell*
13 *Biol* 27, 645-657. 10.1016/j.tcb.2017.05.001.
- 14 Ng, K.M., Ferreyra, J.A., Higginbottom, S.K., Lynch, J.B., Kashyap, P.C., Gopinath, S., Naidu, N.,
15 Choudhury, B., Weimer, B.C., Monack, D.M., and Sonnenburg, J.L. (2013). Microbiota-liberated host
16 sugars facilitate post-antibiotic expansion of enteric pathogens. *Nature* 502, 96-99.
17 10.1038/nature12503.
- 18 Pacheco, A.R., Curtis, M.M., Ritchie, J.M., Munera, D., Waldor, M.K., Moreira, C.G., and Sperandio, V.
19 (2012). Fucose sensing regulates bacterial intestinal colonization. *Nature* 492, 113-117.
20 10.1038/nature11623.
- 21 Pal, R.R., Baidya, A.K., Mamou, G., Bhattacharya, S., Socol, Y., Kobi, S., Katsowich, N., Ben-Yehuda, S.,
22 and Rosenshine, I. (2019). Pathogenic *E. coli* Extracts Nutrients from Infected Host Cells Utilizing
23 Injectisome Components. *Cell* 177, 683-696 e618. 10.1016/j.cell.2019.02.022.
- 24 Passalacqua, K.D., Charbonneau, M.E., and O'Riordan, M.X.D. (2016). Bacterial Metabolism Shapes the
25 Host-Pathogen Interface. *Microbiol Spectr* 4. 10.1128/microbiolspec.VMBF-0027-2015.
- 26 Patwa, L.G., Fan, T.J., Tchaptchet, S., Liu, Y., Lussier, Y.A., Sartor, R.B., and Hansen, J.J. (2011). Chronic
27 intestinal inflammation induces stress-response genes in commensal *Escherichia coli*.
28 *Gastroenterology* 141, 1842-1851 e1841-1810. 10.1053/j.gastro.2011.06.064.
- 29 Perez-Lopez, A., Behnsen, J., Nuccio, S.P., and Raffatellu, M. (2016). Mucosal immunity to pathogenic
30 intestinal bacteria. *Nat Rev Immunol* 16, 135-148. 10.1038/nri.2015.17.
- 31 Pizer LI, P.M. (1964). Nutritional and regulatory aspects of serine metabolism in *Escherichia coli*. *J*
32 *Bacteriol* 88, 611-619. 10.1128/JB.88.3.611-619.1964.
- 33 Prüss, B.M., Nelms, J.M., Park, C., and Wolfe, A.J. (1994). Mutations in NADH-ubiquinone
34 oxidoreductase of *Escherichia coli* affect growth on mixed amino acids. *J Bacteriol* 176, 2143-2150.
35 10.1128/jb.176.8.2143-2150.1994.
- 36 Rigottier-Gois, L. (2013). Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. *ISME J* 7,

- 1 1256-1261. 10.1038/ismej.2013.80.
- 2 Rodriguez, A.E., Ducker, G.S., Billingham, L.K., Martinez, C.A., Mainolfi, N., Suri, V., Friedman, A.,
3 Manfredi, M.G., Weinberg, S.E., Rabinowitz, J.D., and Chandel, N.S. (2019). Serine Metabolism
4 Supports Macrophage IL-1beta Production. *Cell Metab* 29, 1003-1011 e1004.
5 10.1016/j.cmet.2019.01.014.
- 6 Schirmer, M., Franzosa, E.A., Lloyd-Price, J., McIver, L.J., Schwager, R., Poon, T.W., Ananthakrishnan,
7 A.N., Andrews, E., Barron, G., Lake, K., et al. (2018). Dynamics of metatranscription in the
8 inflammatory bowel disease gut microbiome. *Nat Microbiol* 3, 337-346. 10.1038/s41564-017-0089-
9 z.
- 10 Schwab, C., Berry, D., Rauch, I., Rennisch, I., Ramesmayer, J., Hainzl, E., Heider, S., Decker, T., Kenner,
11 L., Muller, M., et al. (2014). Longitudinal study of murine microbiota activity and interactions with the
12 host during acute inflammation and recovery. *ISME J* 8, 1101-1114. 10.1038/ismej.2013.223.
- 13 Sonnenburg, J., Xu, J., Leip, D., Chen, C., Westover, B., Weatherford, J., Buhler, J., and Gordon, J.
14 (2005). Glycan foraging in vivo by an intestine-adapted bacterial symbiont. *Science* 307, 1955-1959.
15 10.1126/science.1109051.
- 16 Stecher, B. (2015). The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in
17 Enteric Pathogen Infection. *Microbiol Spectr* 3. 10.1128/microbiolspec.MBP-0008-2014.
- 18 Steimle, A., De Sciscio, A., Neumann, M., Grant, E.T., Pereira, G.V., Ohno, H., Martens, E.C., and Desai,
19 M.S. (2021). Constructing a gnotobiotic mouse model with a synthetic human gut microbiome to
20 study host-microbe cross talk. *STAR Protoc* 2, 100607. 10.1016/j.xpro.2021.100607.
- 21 Sugihara, K., and Kamada, N. (2021). Diet-Microbiota Interactions in Inflammatory Bowel Disease.
22 *Nutrients* 13. 10.3390/nu13051533.
- 23 Sugihara, K., Morhardt, T.L., and Kamada, N. (2018). The Role of Dietary Nutrients in Inflammatory Bowel
24 Disease. *Front Immunol* 9, 3183. 10.3389/fimmu.2018.03183.
- 25 Thiennimitr, P., Winter, S.E., Winter, M.G., Xavier, M.N., Tolstikov, V., Huseby, D.L., Sterzenbach, T., Tsois,
26 R.M., Roth, J.R., and Baumler, A.J. (2011). Intestinal inflammation allows *Salmonella* to use
27 ethanolamine to compete with the microbiota. *Proc Natl Acad Sci U S A* 108, 17480-17485.
28 10.1073/pnas.1107857108.
- 29 Tsai, Y.H., Czerwinski, M., Wu, A., Dame, M.K., Attili, D., Hill, E., Colacino, J.A., Nowacki, L.M., Shroyer,
30 N.F., Higgins, P.D.R., et al. (2018). A Method for Cryogenic Preservation of Human Biopsy
31 Specimens and Subsequent Organoid Culture. *Cell Mol Gastroenterol Hepatol* 6, 218-222 e217.
32 10.1016/j.jcmgh.2018.04.008.
- 33 Van der Sluis, M., De Koning, B.A., De Bruijn, A.C., Velcich, A., Meijerink, J.P., Van Goudoever, J.B.,
34 Buller, H.A., Dekker, J., Van Seuningen, I., Renes, I.B., and Einerhand, A.W. (2006). Muc2-deficient
35 mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection.
36 *Gastroenterology* 131, 117-129. 10.1053/j.gastro.2006.04.020.

- 1 Vich Vila A, I.F., Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Jiang X,
2 Tigchelaar EF, Dekens J, Peters V, Voskuil MD, Visschedijk MC, van Dullemen HM, Keszthelyi D,
3 Swertz MA, Franke L, Alberts R, Festen EAM, Dijkstra G, Masclee AAM, Hofker MH, Xavier RJ, Alm
4 EJ, Fu J, Wijmenga C, Jonkers DMAE, Zhernakova A, Weersma RK (2018). Gut microbiota
5 composition and functional changes in inflammatory bowel disease and irritable bowel syndrome.
6 *Sci Transl Med* 19 (10), eaap8914. 10.1126/scitranslmed.aap8914.
- 7 Viladomiu, M., Kivolowitz, C., Abdulhamid, A., Dogan, B., Victorio, D., Castellanos, J., Woo, V., Teng, F.,
8 Tran, N., Sczesnak, A., et al. (2017). IgA-coated E. coli enriched in Crohn's disease spondyloarthritis
9 promote T H 17-dependent inflammation. *Sci Transl Med* 9, eaaf9655. 10.1126/scitranslmed.aaf9655.
- 10 Viladomiu, M., Metz, M.L., Lima, S.F., Jin, W.B., Chou, L., Bank, J.R.I.L.C., Guo, C.J., Diehl, G.E.,
11 Simpson, K.W., Scherl, E.J., and Longman, R.S. (2021). Adherent-invasive E. coli metabolism of
12 propanediol in Crohn's disease regulates phagocytes to drive intestinal inflammation. *Cell Host*
13 *Microbe* 29, 607-619 e608. 10.1016/j.chom.2021.01.002.
- 14 Watson, C.L., Mahe, M.M., Munera, J., Howell, J.C., Sundaram, N., Poling, H.M., Schweitzer, J.I.,
15 Vallance, J.E., Mayhew, C.N., Sun, Y., et al. (2014). An in vivo model of human small intestine using
16 pluripotent stem cells. *Nat Med* 20, 1310-1314. 10.1038/nm.3737.
- 17 Yang, M., and Vousden, K.H. (2016). Serine and one-carbon metabolism in cancer. *Nat Rev Cancer* 16,
18 650-662. 10.1038/nrc.2016.81.
- 19 Ze, X., Duncan, S.H., Louis, P., and Flint, H.J. (2012). *Ruminococcus bromii* is a keystone species for the
20 degradation of resistant starch in the human colon. *ISME J* 6, 1535-1543. 10.1038/ismej.2012.4.

21
22

1 **Figure legends**

2

3 **Figure 1. L-serine metabolism is disturbed in the gut microbiota of IBD patients**

4 (A) Metagenomics, metatranscriptomics, and metabolomics data were downloaded from the public
5 resource, the second phase of the Integrative Human Microbiome Project (HMP2 or iHMP) – the
6 Inflammatory Bowel Disease Multi'omics Database.

7 (B) Abundance of Enterobacteriaceae and *E. coli* in the metagenomics database.

8 (C) Abundance of PHGDH, SHMT, and SDH in the metagenomics database (left). Schematic of L-serine
9 metabolism (right).

10 (D) Abundance of PHGDH, SHMT, and SDH in the metatranscriptomics database.

11 (E) Abundance of fecal amino acids in the metabolomics database. The heatmap indicates the fold
12 change (UC or CD/non-IBD).

13 Dots indicate individual people, with median. The numbers in parentheses indicate the number of null
14 values. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ by Kruskal–Wallis test with Dunn test for multiple comparisons.

15 PHGDH, phosphoglycerate dehydrogenase; SHMT, serine hydroxymethyltransferase; SDH, serine
16 dehydratase. See also **Figure S1**.

17

18 **Figure 2. Deprivation of dietary L-serine exacerbates gut inflammation in DSS-induced colitis**
19 **through the gut microbiota**

20 (A) SPF C57BL/6 mice were fed the control diet (Ctrl) or the Δ Ser diet for 3 days, then given 1.5% DSS
21 for 5 days, followed by conventional water for 2 days. On day 7 post-DSS, all mice were euthanized.

22 (B and C) Body weight and DAI were monitored during the 5-day DSS treatment.

23 (D–F) Colon length, representative histological images of colon sections (scale bar, 200 μ m), and
24 histology scores were evaluated.

25 (G) GF Swiss Webster mice were fed a Ctrl diet or a Δ Ser diet for 3 days and then treated with 1.5% DSS
26 for 5 days. On day 5 post-DSS, all mice were euthanized.

27 (H–J) Colon length, representative histological images of colon sections (Scale bar, 200 μ m), and
28 histology scores were assessed.

29 (B–D and H–J) Data pooled from two independent experiments (N = 7–10). (E) Data from an independent
30 experiment (N = 5). Dots indicate individual mice, with mean \pm SEM. N.S., not significant, * $p < 0.05$, ** p
31 < 0.01 , *** $p < 0.001$ by 1-way ANOVA or 2-way ANOVA with Tukey post hoc test. See also **Figure S2**.

32

33 **Figure 3. Deprivation of dietary L-serine fosters blooms of pathotype *E. coli* and *A. muciniphila* in**
34 **the inflamed gut**

35 (A) Feces were collected from Ctrl diet– and Δ Ser diet–fed mice with and without DSS treatment, and
36 DNA was isolated. Gut microbiota was analyzed by 16S rRNA sequencing.

1 (B) Significantly enriched bacterial taxa in Ctrl diet–fed mice (blue bars) and Δ Ser diet–fed mice (red
2 bars) were identified by LEfSe analysis.
3 (C) The relative abundance of *A. muciniphila* and *E. coli* was each quantified by qPCR.
4 (D) The heat map shows the abundance of *E. coli* virulence genes in Δ Ser diet–fed colitis mice compared
5 to Ctrl diet–fed colitis mice.
6 Dots indicate individual mice, with mean \pm SEM. N.S., not significant. *** $p < 0.001$ by 1-way ANOVA with
7 Tukey post hoc test.

8

9 **Figure 4. Disruption of colonic mucus barrier under L-serine starvation enhances the**
10 **encroachment of AIEC to the epithelial niche.**

11 (A) Relative abundance of *A. muciniphila* and *E. coli* during DSS treatment were each assessed by qPCR.
12 (B and C) Colonic sections were stained with AB/PAS, and the thickness of the inner mucus layer was
13 measured (scale bar, 100 μ m).
14 (D) Intestinal permeability was assessed with FITC–dextran.
15 (E) Immunostaining (MUC2, green; DAPI, blue) and FISH (EUB338 probe, red,) of Carnoy's solution–
16 fixed colonic sections (scale bar, 100 μ m).
17 (F) SPF C57BL/6 mice were fed the Ctrl diet or the Δ Ser diet for 3 days, then given 1.5% DSS for 5 days,
18 followed by conventional water for 2 days. Mice were infected with each strain of *E. coli* (1×10^9
19 CFU/mouse) on days 5 and 6. On day 7 post-DSS, all mice were euthanized.
20 (G) Homogenates of colon tissues were cultured on LB agar plates supplemented with ampicillin or
21 streptomycin. The number of viable bacteria was estimated by counting the CFUs and calculating the
22 fold change (Δ Ser diet/Ctrl diet).
23 Dots indicate individual mice, with mean \pm SEM. N.S., not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$
24 by 1-way ANOVA with Tukey post hoc test or unpaired *t* test.

25

26 **Figure 5. *A. muciniphila*-mediated mucus disruption facilitates adhesion of AIEC to IECs**

27 (A) Assembly of anaerobic coculture system. The human-derived colonoid monolayer (HCM) from each
28 donor (colon-81 and colon-88) was differentiated for 6 days by differentiation media (DM) with or without
29 antibiotics (Abx). *A. muciniphila* was infected for 18 h, and then AIEC LF82 was infected for 1–3 h.
30 (B) Immunofluorescence staining of MUC2 (green), *E. coli* (red), and DAPI (blue). Scale bar, 100 μ m
31 (XYZ axis) and 20 μ m (XZ axis).
32 (C) Cell-associated AIEC LF82 was cultured on LB agar plates supplemented with ampicillin. The number
33 of viable bacteria was estimated by counting the CFUs.
34 Dots indicate individual mice, with mean \pm SEM. N.S., not significant. * $p < 0.05$, *** $p < 0.001$ by unpaired
35 *t* test.

36

1 **Figure 6. AIEC and *A. muciniphila* cooperatively exacerbate colitis under L-serine restriction**

2 (A) Experimental protocol and the composition of the nonmucolytic synthetic human gut microbiota
3 (NmSM) for the gnotobiotic mouse experiments.

4 (B and C) Body weight and colon length were measured 7 days post DSS treatment.

5 (D) Intestinal permeability was assessed with FITC–dextran.

6 (E and F) Representative histological images of colonic sections stained with HE (scale bar, 200 μ m) and
7 the histology scores.

8 (G and H) The relative abundance of each bacterial strain at baseline and post-DSS treatment was
9 assessed by qPCR. Fold change of *E. coli* abundance (post-DSS/baseline) was calculated.

10 (I) Homogenates of feces or colon tissues were cultured on LB agar plates. The number of viable bacteria
11 was estimated by counting the CFUs.

12 Dots indicate individual mice, with mean \pm SEM. N.S., not significant. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$
13 by 1-way ANOVA with Tukey post hoc test. See also **Figure S3**.

14
15 **Figure 7. L-serine utilization by AIEC is a partial requirement for the exacerbation of colitis under**
16 **L-serine deprivation**

17 (A and B) *E. coli* strains were cultured with and without T84 cells. After 1–5 h infection, the CFUs of total
18 bacteria, including adhered and nonadhered bacteria, were counted.

19 (C) AIEC LF82 was monocultured or cocultured with the human-derived colonoid monolayer (HCM) for 3
20 h, and the transcriptomic profiles were evaluated by RNA-seq. The heat map shows fold changes of L-
21 serine metabolism genes (LF82 + HCM/LF82).

22 (D) LF82 WT or Δ TS mutant strains were infected in T84 cells for 5 h, and then the CFUs of total bacteria
23 were counted.

24 (E) Fold changes of intracellular L-serine after infection of T84 cells with AIEC strain LF82.

25 (F) T84 cells were infected with LF82 WT or Δ TS mutant strains. After 3 h, adhesion bacteria were
26 counted.

27 (G) T84 cells were infected with LF82 WT or Δ TS mutant strains. After 1 h, the cells were cultured with
28 gentamicin (100 mg/mL) for 24 h. Intracellular bacteria were plated on LB agar plates and counted.

29 (H) LF82 and T84 cells were cocultured in the Ctrl media or Δ Ser media. After a 3 h infection, adhesion
30 and invasion bacteria were plated on LB agar plates and counted.

31 (I) Experimental design. GF mice were colonized by nonmucolytic synthetic human gut microbiota
32 (NmSM) and *A. muciniphila* with LF82 WT or Δ TS mutant strains.

33 (J) On day 7 post-DSS, all mice were euthanized, and the LF82 burden in the colon and feces was
34 assessed.

35 (K and L) Body weight and colon length.

36 (M) Intestinal permeability was evaluated by FITC–dextran assay.

1 (N and O) Representative histological images (scale bar, 200 μ m) and histology scores were evaluated.
2 Dots indicate individual mice, with mean \pm SEM. N.S., not significant. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$
3 by 1-way ANOVA with Tukey post hoc test or unpaired t test. See also **Figure S4**.

4

1 **Supplementary Figure Legends**

2

3 **Figure S1. IBD-associated AIEC LF82 preferentially uses L-serine for its growth, Related to Figure**
4 **1**

5 AIEC strain LF82 was cultured in DMEM/F12 media for 1 or 3 h and then the concentrations of amino
6 acids were measured. Dots indicate individual samples with mean \pm SEM. . * $p < 0.05$, ** $p < 0.01$, *** $p <$
7 0.001 by 1-way ANOVA with Tukey post hoc test.

8

9 **Figure S2. Dietary L-serine restriction-induced exacerbation of colitis is dependent on the gut**
10 **microbiota, Related to Figure 2**

11 (A) SPF C57BL/6 mice were treated with drinking water containing a cocktail of antibiotics (ampicillin,
12 neomycin, vancomycin) and metronidazole by oral gavage for 7 days. Mice were then fed the Ctrl diet or
13 the Δ Ser diet and treated with DSS for 5 days. During DSS treatment, mice were given a cocktail of
14 antibiotics (ampicillin, neomycin, vancomycin, metronidazole) by oral gavage. On day 5 post-DSS, all
15 mice were euthanized.

16 (B) Bacterial burden of feces after treatment with antibiotics was evaluated by qPCR.

17 (C) Body weight was measured during DSS treatment.

18 (D–F) colonic length, representative histological images of HE sections (scale bar, 200 μ m), and
19 histological scores.

20 Dots indicate individual mice, with mean \pm SEM. N.S., not significant. *** $p < 0.001$ by unpaired t test.

21

22 **Figure S3. AIEC and *A. muciniphila* enhance gut inflammation in a dietary L-serine-dependent**
23 **manner, Related to Figure 6**

24 (A) Experimental protocol and the composition of the nonmucolytic synthetic human gut microbiota
25 (NmSM) for the gnotobiotic mouse experiments.

26 (B and C) AB/PAS staining and immunofluorescence staining of colonic sections (MUC2, green; DAPI,
27 blue). The thickness of the inner mucus layer was measured (scale bar, 100 μ m).

28 (D) Homogenates of colon tissues were cultured on LB agar plates. The number of viable bacteria was
29 estimated by counting the CFUs.

30 (E and F) Body weight and colon length (were measured 7 days post-DSS treatment.

31 (G and H) Representative images of colonic sections stained with HE (scale bar, 200 μ m) and histology
32 scores.

33 (I) Intestinal permeability was assessed with FITC–dextran.

34 Dots indicate individual mice, with mean \pm SEM. N.S., not significant. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$
35 by 1-way ANOVA with Tukey post hoc test.

36

1 **Figure S4. The transcriptomic profiles of AIEC and the human-derived colonoid monolayer (HCM),**
2 **Related to Figure 7**


3 (A) Experimental design. LF82 was cultured with or without HCM for 3 h. Uninfected HCM was used as
4 a control to assess the impact of LF82 infection in transcriptome of HCM.

5 (B) Volcano plot shows the significantly upregulated and downregulated genes in LF82-associated with
6 HCM (fold change >2 and SNR >1).

7 (C) Significantly upregulated and downregulated pathways of LF82 transcriptomes identified by GO
8 enrichment analysis.

9 (D) Volcano plot shows the significantly up- and downregulated genes in the infected-HCM (fold change
10 >2 and SNR >1).

11 (E) Significantly upregulated and downregulated pathways of HCM transcriptomes identified by GO
12 enrichment analysis.






Figure 2. Deprivation of dietary L-serine exacerbates gut inflammation in DSS-induced colitis through the gut microbiota

(A) SPF C57BL/6 mice were fed the control diet (Ctrl) or the Δ Ser diet for 3 days, then given 1.5% DSS for 5 days, followed by conventional water for 2 days. On day 7 post-DSS, all mice were euthanized.

(B and C) Body weight and DAI were monitored during the 5-day DSS treatment.


(D–F) Colon length, representative histological images of colon sections (scale bar, 200 μ m), and histology scores were evaluated.

(G) GF Swiss Webster mice were fed a Ctrl diet or a Δ Ser diet for 3 days and then treated with 1.5% DSS for 5 days. On day 5 post-DSS, all mice were euthanized.


(H–J) Colon length, representative histological images of colon sections (Scale bar, 200 μ m), and histology scores were assessed.

(B–D and H–J) Data pooled from two independent experiments (N = 7–10). (E) Data from an independent experiment (N = 5). Dots indicate individual mice, with mean \pm SEM. N.S., not significant, * p < 0.05, ** p < 0.01, *** p < 0.001 by 1-way ANOVA, 2-way ANOVA with Tukey post hoc test, or unpaired t test. See also **Figure S2**.


A



B



C



D




Figure 3. Deprivation of dietary L-serine fosters blooms of pathotype *E. coli* and *A. muciniphila* in the inflamed gut

(A) Feces were collected from Ctrl diet- and Δ Ser diet-fed mice with and without DSS treatment, and DNA was isolated. Gut microbiota was analyzed by 16S rRNA sequencing.

(B) Significantly enriched bacterial taxa in Ctrl diet-fed mice (blue bars) and Δ Ser diet-fed mice (red bars) were identified by LEfSe analysis.

(C) The relative abundance of *A. muciniphila* and *E. coli* was each quantified by qPCR.

(D) The heat map shows the abundance of *E. coli* virulence genes in Δ Ser diet-fed colitis mice compared to Ctrl diet-fed colitis mice.

Dots indicate individual mice, with mean \pm SEM. N.S., not significant. *** $p < 0.001$ by 1-way ANOVA with Tukey post hoc test.




Figure 4. Disruption of colonic mucus barrier under L-serine starvation enhances the encroachment of AIEC to the epithelial niche.

(A) Relative abundance of *A. muciniphila* and *E. coli* during DSS treatment were each assessed by qPCR. (B and C) Colonic sections were stained with AB/PAS, and the thickness of the inner mucus layer was measured (scale bar, 100 μm). (D) Intestinal permeability was assessed with FITC-dextran. (E) Immunostaining (MUC2, green; DAPI, blue) and FISH (EUB338 probe, red,) of Carnoy's solution-fixed colonic sections (scale bar, 100 μm). (F) SPF C57BL/6 mice were fed the Ctrl diet or the Δ Ser diet for 3 days, then given 1.5% DSS for 5 days, followed by conventional water for 2 days. Mice were infected with each strain of *E. coli* (1×10^9 CFU/mouse) on days 5 and 6. On day 7 post-DSS, all mice were euthanized. (G) Homogenates of colon tissues were cultured on LB agar plates supplemented with ampicillin or streptomycin. The number of viable bacteria was estimated by counting the CFUs and calculating the fold change (Δ Ser diet/Ctrl diet). Dots indicate individual mice, with mean \pm SEM. N.S., not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ by 1-way ANOVA with Tukey post hoc test or unpaired *t* test.




Figure 5. *A. muciniphila*-mediated mucus disruption facilitates adhesion of AIEC to IECs.

(A) Assembly of anaerobic coculture system. The human-derived colonoid monolayer (HCM) from each donor (colon-81 and colon-88) was differentiated for 6 days by differentiation media (DM) with or without antibiotics (Abx). *A. muciniphila* was infected for 18 h, and then AIEC LF82 was infected for 1–3 h.

(B) Immunofluorescence staining of MUC2 (green), *E. coli* (red), and DAPI (blue). Scale bar, 100 μm (XYZ axis) and 20 μm (XZ axis).

(C) Cell-associated AIEC LF82 was cultured on LB agar plates supplemented with ampicillin. The number of viable bacteria was estimated by counting the CFUs.

Dots indicate individual mice, with mean ± SEM. N.S., not significant. * $p < 0.05$, *** $p < 0.001$ by unpaired t test.




Figure 6. AIEC and *A. muciniphila* cooperatively exacerbate colitis under L-serine restriction.

(A) Experimental protocol and the composition of the nonmucolytic synthetic human gut microbiota (NmSM) for the gnotobiotic mouse experiments.

(B and C) Body weight and colon length were measured 7 days post DSS treatment.

(D) Intestinal permeability was assessed with FITC–dextran.

(E and F) Representative histological images of colonic sections stained with HE (scale bar, 200 μ m) and the histology scores.

(G and H) The relative abundance of each bacterial strain at baseline and post-DSS treatment was assessed by qPCR. Fold change of *E. coli* abundance (post-DSS/baseline) was calculated.

(I) Homogenates of feces or colon tissues were cultured on LB agar plates. The number of viable bacteria was estimated by counting the CFUs.

Dots indicate individual mice, with mean \pm SEM. N.S., not significant. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ by 1-way ANOVA with Tukey post hoc test. See also **Figure S3**.




Figure 7. L-serine utilization by AIEC is a partial requirement for the exacerbation of colitis under L-serine deprivation.

(A and B) *E. coli* strains were cultured with and without T84 cells. After 1–5 h infection, the CFUs of total bacteria, including adhered and nonadhered bacteria, were counted.

(C) AIEC LF82 was monocultured or cocultured with the human-derived colonoid monolayer (HCM) for 3 h, and the transcriptomic profiles were evaluated by RNA-seq. The heat map shows fold changes of L-serine metabolism genes (LF82 + HCM/LF82).

(D) LF82 WT or ΔTS mutant strains were infected in T84 cells for 5 h, and then the CFUs of total bacteria were counted.

(E) Fold changes of intracellular L-serine after infection of T84 cells with AIEC strain LF82.

(F) T84 cells were infected with LF82 WT or ΔTS mutant strains. After 3 h, adhesion bacteria were counted.

(G) T84 cells were infected with LF82 WT or ΔTS mutant strains. After 1 h, the cells were cultured with gentamicin (100 μg/mL) for 24 h. Intracellular bacteria were plated on LB agar plates and counted.

(H) LF82 and T84 cells were cocultured in the Ctrl media or ΔSer media. After a 3 h infection, adhesion and invasion bacteria were plated on LB agar plates and counted.

(I) Experimental design. GF mice were colonized by nonmucolytic synthetic human gut microbiota (NmSM) and *A. muciniphila* with LF82 WT or ΔTS mutant strains.

(J) On day 7 post-DSS, all mice were euthanized, and the LF82 burden in the colon and feces was assessed.

(K and L) Body weight and colon length.

(M) Intestinal permeability was evaluated by FITC–dextran assay.

(N and O) Representative histological images (scale bar, 200 μm) and histology scores were evaluated.

Dots indicate individual mice, with mean ± SEM. N.S., not significant. **p* < 0.05, ***p* < 0.01, ****p* < 0.001 by 1-way ANOVA with Tukey post hoc test or unpaired *t* test. See also **Figure S4**.